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ABSTRACT
The Impact of Diffuse Large B-Cell Lymphoma on Primary Care and Costs of Chronic
Conditions in Elderly Medicare Beneficiaries
Rahul Garg
Diffuse Large B-Cell Lymphoma (DLBCL) is an aggressive form of Non-Hodgkin’s
lymphoma with a median age of diagnosis of 67 years. The intensive treatment of DLBCL can
negatively influence elderly patients’ preventive and chronic care, which can increase the costs
of different chronic conditions. DLBCL diagnosis and treatment can affect patients’ visits to
their primary care providers (PCPs) and other specialists, which are important for patients’
preventive screenings and chronic care. Further, having DLBCL increases the risk for breast
cancer, and DLBCL treatment is associated with cardiotoxicity and increases the risk of
osteoporosis and fractures. Thus, mammography and bone mineral density testing (BDT) are
critical areas of screening for individuals with DLBCL, and a change in visits to PCPs can affect
preventive and chronic care. Along with these challenges to care quality in DLBCL patients, the
costs of different chronic conditions may increase. Currently, there is a dearth of studies that
have examined visits to PCPs and specialists, preventive screenings, and costs of chronic
conditions among DLBCL patients as compared to individuals with no cancer. We conducted
this study to reduce this knowledge gap and to provide actionable strategies to improve the
preventive care and reduce the costs of DLBCL patients. The three specific aims of this study
were to: 1) analyze the impact of DLBCL on visits to PCPs and specialists over a three-year
period of DLBCL diagnosis, treatment, and follow-up; 2) examine the receipt of mammography
and BDT by female DLBCL patients during two years after DLBCL diagnosis; and 3) examine
the costs of common chronic conditions and total cost over a three-year period of DLBCL
diagnosis, treatment, and follow-up among fee-for-service elderly Medicare beneficiaries with

newly diagnosed DLBCL as compared to Medicare beneficiaries without cancer. We used a
retrospective longitudinal study design for aim 1 and aim 3; and a cross-sectional design for aim
2 of this study. We used Surveillance, Epidemiology and End Results (SEER) program (20022013) data linked with Medicare administrative claims and the Area Health Resource Files. In
the first aim, DLBCL patients (n = 5,455) were more likely to visit PCPs (AOR [95%CI]: 1.25
[1.18, 1.31]) and had a greater number of visits to PCPs (β, SE: 0.384, -0.014) than non-cancer
patients (n = 14,770). Further, DLBCL patients were more likely to have any visit to a
cardiologist (AOR [95%CI]: 1.40 [1.32, 1.47]), endocrinologist (1.43, [1.21, 1.70]), and
pulmonologist (1.51 [1.36, 1.67]) than non-cancer patients. Among DLBCL patients, the number
of PCP visits markedly increased during the treatment period compared to the baseline period (β,
SE: 0.491, -0.028) and then decreased to baseline levels (-0.464, -0.022). In the second aim,
although DLBCL and its treatment increase the risk of breast cancer and bone density loss,
mammography and BDT did not differ between women with DLBCL (mammography: 59.8%,
BDT: 18.5%) and no cancer (mammography: 60.2%, BDT: 19.6%; p > .05). After adjusting for
PCP visits, DLBCL patients were less likely to have mammography (AOR [95%CI]: 0.82 [0.71,
0.94]) and BDT (0.80 [0.71, 0.90]) than non-cancer patients. Further, those with more primary
care physician visits were more likely to have mammography (1.62 [1.48, 1.77]) and BDT (1.60
[1.50, 1.71]). In the third aim, the net total cost of DLBCL patients increased substantially during
the treatment period ($60,746.1). DLBCL patients had significantly higher cost of heart
conditions but lower costs of hypertension, asthma/chronic obstructive pulmonary disease, any
mental illness, and diabetes than non-cancer patients (all p< .001). To summarize, our study
found that the visits to PCPs and specialists were much higher for DLBCL than non-cancer
patients, which drastically increased during the DLBCL treatment period for chronic care.

Treatment adverse effects and more frequent contact with healthcare system may have increased
the visits to PCPs and specialists. Female DLBCL patients received lower preventive care, which
may be due to prioritization of DLBCL treatment. There is a need to increase the
recommendations for mammography and BDT to reduce the morbidity and mortality from breast
cancer and fractures. DLBCL treatment cardiotoxicity may have increased the cost of heart
conditions, while suboptimal care may have reduced the short term costs of other common
chronic conditions. Interventions are needed to increase the preventive and chronic care among
elderly DLBCL patients.
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Chapter 1: Introduction
1.1 Background
Diffuse Large B-Cell Lymphoma (DLBCL) is an aggressive and the most common
subtype of Non-Hodgkin’s Lymphoma, accounting for about 30-40% of all newly diagnosed
cases.1 Newly diagnosed DLBCL requires intensive treatment with chemo-immunotherapy,
radiotherapy, or stem cell transplant.2,3 Due to these treatments, many DLBCL cases (~ 60%) are
cured and DLBCL patients have a 5-year survival rate of 60.5%.1,4 However, aggressive
treatment of DLBCL can lead to many adverse consequences5 such as secondary cancers,6 posttraumatic stress,7 and poor quality of life.8 Further, most DLBCL patients are above 65 years of
age,910 who have at least one (82.0%) or two or more (67.3%) chronic physical and mental
conditions (multimorbidity).11,12 The National Cancer Institute (NCI) comorbidity score, which
measures the number and severity of 15 non-cancer comorbidities, ranged from 1-3 for a
majority of DLBCL patients.3
The treatment side effects and presence of multiple chronic conditions require regular
visits to multiple providers for chronic and preventive care. The role of multiple provider
specialties in providing care to cancer patients has been emphasized by the Institute of Medicine
(IOM) in its report on delivering high-quality cancer care.13 These different providers include
oncologists (e.g., hematology, medical oncology, surgical oncology, and radiation oncology),
primary care physicians (PCPs, e.g., general internal medicine, family medicine), other physician
specialties (e.g., endocrinology, pulmonology, and ophthalmology - hereafter referred to as
“other medical specialists”), nurses, and caregivers.13 A diagnosis of DLBCL can affect patients’

1

visits to different provider specialties, thereby negatively affecting their chronic and preventive
care.14
Less chronic and preventive care can decrease the short term costs but increase the long
term costs of chronic conditions, which has not been previously investigated. Elderly individuals
with multiple chronic conditions bear a significant cost burden due to these multiple illnesses,
which can be disproportionately affected by a diagnosis of cancer. DLBCL treatment increases
the risk of breast cancer6,15 and osteoporosis16 and can increase the severity of other chronic
conditions leading to higher costs. Conversely, prioritization of DLBCL treatment can eclipse
patients’ chronic care and can reduce the short term costs of certain chronic conditions. There is
a lack of research on how DLBCL diagnosis affects patients’ visits to different provider
specialties, their preventive care, and the resulting costs of chronic conditions among elderly
Medicare beneficiaries with DLBCL. Therefore, the overall goal of this dissertation is to analyze
the impact of newly diagnosed DLBCL on visits to PCPs and specialists, preventive care, and
costs of chronic conditions among Medicare beneficiaries with DLBCL as compared to
beneficiaries without cancer.
The dissertation is organized in five chapters. Chapter 1 briefly describes the
epidemiology and treatment of DLBCL, need for this study, data sources, and the theoretical
framework used for this study. Chapter 2 focuses on the change in visits to PCPs and other
medical specialists over a 3-year period of DLBCL diagnosis, treatment, and follow-up among
DLBCL patients as compared to those without cancer. Chapter 3 describes the receipt of
mammography and bone mineral density testing (BDT) among women with DLBCL as
compared to women without cancer. Chapter 4 highlights the impact of DLBCL on the costs of
common chronic conditions and total cost before DLBCL diagnosis, during DLBCL treatment,
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and at follow-up periods among DLBCL patients as compared to those without cancer. Finally,
chapter 5 summarizes the findings from chapter 2, 3, and 4 and includes the implications and
recommendations for future research. Chapter 5 also consists of the limitations and strengths of
this study.
1.1.1 Epidemiology of DLBCL
Non-Hodgkin’s Lymphoma (NHL) is the most prevalent hematologic cancer in the US
with 72,240 new cases diagnosed in 2017.17 DLBCL is the most common subtype of NHL,
accounting for about one-third of NHL cases.1 The incidence of DLBCL is approximately 7
cases per 100,000 individuals in the United States (US).18 Similar to most other subtypes of
NHL, DLBCL is more prevalent in males (55%) than females. The incidence of DLBCL
increases with age, with the median age of diagnosis being 67 years.9 However, African
Americans are more likely to be diagnosed at <60 years of age (65%) than Whites (37%).19 Most
DLBCL cases with localized disease and approximately half of those with advanced stage
disease are cured by treatment, which leads to a moderate five-year survival rate of 60.5%.3 The
survival rates have been found to be better for women (61%) than men (58%) and for Whites
(60%) than African Americans (50%).19 Age at diagnosis >60 years, African American race,
male sex, and advanced stage are associated with worse survival among DLBCL patients.19
1.1.2 Treatment of DLBCL
The overall treatment period of DLBCL among elderly patients lasts for approximately
six months from the date of DLBCL diagnosis.3 The treatment pattern for elderly patients with
DLBCL includes chemo-immunotherapy (49%), chemotherapy only (23%), immunotherapy only
(5%), or no treatment (23%) depending upon the stage of cancer and patient’s age.3 About 3040% of DLBCL patients present with limited stage (Ann Arbor stage I or II) disease.19 These
3

patients are usually treated with chemo-immunotherapy (3-6 cycles) using R-CHOP
(cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab) with or without
radiotherapy.3,20 Advanced stage DLBCL (60-70% cases) are given six cycles of R-CHOP or are
recommended to be enrolled in a clinical trial. Radiotherapy to treat initially bulky disease (neoadjuvant chemotherapy) may also be employed for advanced DLBCL. If responsive, the patients
are observed for disease progression with positron emission tomography/computed tomography
(PET-CT) scan. All refractory or relapsed cases are considered for high dose chemotherapy with
either autologous (patient’s) or allogeneic (someone else’s) stem cell transplant.20
1.1.3 Visits to PCPs and Other Medical Specialists by DLBCL Patients
The adverse sequelae of DLBCL treatments and presence of multimorbidity in elderly
DLBCL patients call for regular visits to PCPs and other medical specialists during and after the
DLBCL treatment period. The patient’s PCP or other medical specialist might have a better
knowledge of patient’s pre-existing chronic conditions, and they may be more effective in
providing care for his/her chronic conditions. Other important roles of PCPs and other medical
specialists for cancer patients include helping with treatment decisions, providing psychosocial
support, and continuing preventive and chronic care.21 The IOM has emphasized the role of
multiple providers and caregivers in providing high-quality cancer care during and after the
cancer treatment period.13
Although physicians trained in family medicine or general internal medicine typically
serve as PCPs, other medical specialists such as cardiologists, pulmonologists, or
endocrinologists, assume an important role in providing health care to elderly individuals, due to
the variety of chronic diseases that may be present (e.g., heart disease, chronic obstructive
pulmonary disease, diabetes). Regular visits to PCPs and other medical specialists are
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recommended for elderly individuals with chronic physical and mental conditions, which should
not be interrupted during the DLBCL treatment and follow-up periods.22,23 However, there is a
lack of studies on the impact of DLBCL diagnosis and treatment on the visits to PCPs and other
medical specialists.
1.1.4 Preventive Care of DLBCL Patients
As outlined by the US Preventive Services Task Force (USPSTF), clinical preventive
services for elderly individuals include a wide range of screenings for chronic diseases and
immunizations24 (Table 1.1). Despite being covered by Medicare, less than half of elderly above
65 years of age have been found to be up-to-date with recommended clinical preventive
services.25 Receipt of preventive services, specifically mammography and BDT, is critical for
women with DLBCL because of their heightened risk of breast cancer and osteoporosis.5,6,15,16
Timely mammography screening and BDT can lead to early diagnosis of breast cancer and can
reduce the risk of fractures in female DLBCL patients.26,27 Hence, it is important to assess the
receipt of mammography and BDT among elderly women with newly diagnosed DLBCL as
compared to women without cancer.
Table 1.1 Selected Preventive Care Services for Adults over 65 years of Age

U.S. Preventive Services Task Force Screening Recommendations
1. Screening for Breast Cancer: Using Film Mammography
Individualize decision to begin biennial screening according to the patient’s circumstances and
values - Women aged 40-49 years.
Biennial screening for women aged 50-74 years.
Women aged ≥75 years - Evidence of benefit is lacking.
2. Screening for Prostate Cancer
Adult males - Do not use prostate-specific antigen (PSA)-based screening for prostate cancer
(2012).
In 2008, the USPSTF had recommended against PSA-based screening for men 75 years and
older in 2008.
3. Screening for Osteoporosis using dual-energy X-ray absorptiometry of the hip and lumbar
spine.
5

Evidence is lacking about optimal intervals for repeated screening.
Women age ≥65 years without previous known fractures or secondary causes of osteoporosis.
Men without previous known fractures or secondary causes of osteoporosis – No
recommendation.
Advisory Committee on Immunization Practices–Recommended Immunizations
4. Annual vaccination for Influenza - All adults

The receipt of screening and preventive health services has been found to vary by the
type of provider seen. Breast cancer patients with outpatient visits to a gynecologist or a PCP
were found more likely to undergo mammograms.28 A study by Earle et al. found that the breast
cancer patients who visited oncologists were more likely to receive mammography while those
who visited a PCP were more likely to receive non-cancer related preventive services such as flu
vaccine, lipid testing, and bone densitometry.29 Similarly, colorectal cancer patients who visited
both PCP and oncologist were more likely to receive appropriate follow-up care for heart failure,
diabetes care, and other preventive services.30-33 Although existing studies have examined the
receipt of preventive care services in patients with breast and colorectal cancer, there is a lack of
research on the association of PCP visits with preventive care of patients with DLBCL.
1.1.5 Costs of Chronic Conditions for DLBCL Patients
Medicare beneficiaries with multiple chronic conditions bear a disproportionate burden of
costs of care.11 For example, 36% of Medicare Part A enrollees have >2 chronic conditions;
however these enrollees account for 86% of total Part A expenditures.34 Similarly, 41% of
Medicare Part B enrollees have >2 chronic conditions; but these enrollees account for
approximately 70% of Part B payments.34 The cost burden of chronic conditions can be
significantly increased by the diagnosis of DLBCL, which increases the risk and severity of
certain chronic conditions. DLBCL patients are more likely to have osteoporosis and fractures
due to chemotherapy and stem cell transplant.16,35,36 Also, the cardiotoxicity of chemotherapy
6

can worsen heart conditions, leading to an increase in costs of these conditions.37 However, the
prioritization of cancer care can reduce the care provided for chronic conditions. For example,
patients with colorectal cancer received lower care for heart conditions, diabetes, and Chronic
Obstructive Pulmonary Disease (COPD),38,39 which can decrease the short term cost of these
conditions. There is a paucity of studies that have investigated the cost of chronic conditions
among cancer survivors as compared to those without cancer. Also, evidence is lacking on the
change in cost of chronic conditions before cancer diagnosis, during cancer treatment, and at
follow-up periods.
Cost estimates of chronic conditions at different phases of cancer care are critical for
resource allocation and setting benchmarks for cost reduction, as supported by the ‘Oncology
Care Model, a new payment and delivery model from the Center for Medicare & Medicaid
Innovation, which aims to increase the quality while reducing the cost of cancer care.40 Our
study will examine the cost of specific chronic conditions and total costs of care, which will
assist in implementing these innovative models of cancer care.
1.2 Specific Aims
The specific aims of this dissertation are as follows:
Specific Aim 1. To examine the impact of DLBCL diagnosis on the visits to PCPs and, among
those with chronic conditions, visits to other medical specialists among Medicare beneficiaries
with DLBCL as compared to beneficiaries without cancer.


Objective 1.1: To examine the impact of DLBCL diagnosis on the visits to PCPs and
other medical specialists among elderly Medicare beneficiaries >66 years of age with
DLBCL as compared to beneficiaries without cancer.



Objective 1.2: To examine the change in visits to PCPs and other medical specialists
before cancer diagnosis, during cancer treatment, and at follow-up periods among elderly
Medicare beneficiaries >66 years of age with DLBCL as compared to beneficiaries
without cancer.

7

Specific Aim 2. To examine the receipt of mammography and BDT by female Medicare
beneficiaries with DLBCL as compared to female beneficiaries without cancer.


Objective 2.1: To investigate the receipt of mammography and the association of PCP
visits with mammography rates among female Medicare beneficiaries with DLBCL
between 66 and 74 years of age as compared to those without cancer.



Objective 2.2: To investigate the receipt of BDT and the association of PCP visits with
BDT rates among female Medicare beneficiaries with DLBCL >66 years of age as
compared to those without cancer.

Specific Aim 3. To evaluate the impact of DLBCL on the costs of common chronic conditions
and total costs among elderly Medicare beneficiaries with DLBCL as compared to those without
cancer.


Objective 3.1: To evaluate the change in costs of specific chronic conditions before
cancer diagnosis, during cancer treatment, and at follow-up periods among Medicare
beneficiaries with DLBCL as compared to those without cancer.



Objective 3.2: To evaluate the change in total costs before cancer diagnosis, during
cancer treatment, and at follow-up periods among Medicare beneficiaries with DLBCL as
compared to those without cancer.

1.3 Study Hypotheses
Aim 1 A previous study among breast cancer patients found that face-to-face visits with PCPs
increased during the active treatment phase as compared to the period before cancer diagnosis.41
Further, visits to PCPs by colorectal patients have been found to increase during the follow-up
period after the cancer treatment is over, as compared to the pre-treatment period.42,43 Based on
the results of these studies, we hypothesized that visits to PCPs and other medical specialists will
increase during both the cancer treatment and follow-up periods as compared to the baseline
period because cancer patients may have higher healthcare needs during the treatment period.
Aim 2 Cancer patients have been found to be more likely to have preventive screenings than
non-cancer patients. For example, breast cancer patients were more likely to receive
mammography (74.0%) and BDT (8.3%) than patients without cancer (41.0% and 6.8%,
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respectively).29 Similarly, colorectal cancer patients were more likely to receive a mammogram
(49.8%) than non-cancer patients (47.4%).33 Hence, we hypothesized that women with DLBCL
will be more likely to receive mammography and BDT than women without cancer.
Women cancer patients with higher visits to PCPs have been found to receive more
preventive screenings.28,29,32 For example, breast cancer patients with more visits to PCPs were
twice as likely to receive mammography28 and colorectal patients with more PCP visits were
twice as likely to receive BDT.31 Hence, we hypothesized that patients with higher visits to PCPs
will be more likely to receive mammography and BDT.
Aim 3 Chemotherapy can worsen heart conditions in DLBCL patients.37 Also, stem cell
transplant and chemotherapy can cause osteoporosis and fractures in DLBCL patients.16 Hence,
for aim 3 we hypothesized that the cost of heart conditions, osteoporosis, and arthritis will
increase during cancer treatment and short follow-up among DLBCL patients. According to
previous studies, colorectal patients received lower care for diabetes and asthma/COPD.38 We
hypothesized that due to lower quality of care, the short term costs of other common chronic
conditions such as diabetes, hypertension, and Asthma/COPD will decrease among DLBCL
patients as compared to those without cancer.
1.4 Data Sources
We linked data from the following data sources for this study: 1) Surveillance
Epidemiology and End-Results Program (SEER) cancer registries; 2) 5% Medicare sample for
patients without any cancer; 3) Medicare claims of SEER and non-cancer patients; and 4) the
Area Health Resource File (AHRF).
1.4.1 Surveillance Epidemiology and End-Results Program (SEER)
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The SEER is an epidemiologic surveillance system representing about 28% of the US
population residing in 20 population-based tumor registries (Alaska Native Tumor Registry,
Arizona Indians, Cherokee Nation-Oklahoma, Connecticut, Detroit, Atlanta-Georgia, Greater
Georgia, Rural Georgia, San Francisco-Oakland, San Jose-Monterey, Greater California, Hawaii,
Iowa, Kentucky, Los Angeles, Louisiana, New Jersey, New Mexico, Seattle-Puget Sound, and
Utah).44 The SEER cancer registries collect information for all the newly diagnosed cancer cases
such as patient’s demographic characteristics, cancer site, date of cancer diagnosis, and cancer
pathology (e.g., stage and grade). This information is included in the Patient Entitlement and
Diagnosis Summary File (PEDSF).
1.4.2 Medicare Sample of Non-Cancer Patients
We also utilized a 5% random sample of Medicare beneficiaries who did not have any
cancer (except basal cell carcinoma) as the comparison group in this study. This sample of noncancer patients was derived from Medicare beneficiaries who resided in the SEER areas. The
individuals in this sample who also appeared in the SEER data are removed.
1.4.3 Medicare Claims
As majority of cancer cases are diagnosed among the elderly population aged 65 years
and above, SEER patients’ Medicare claims can be utilized to obtain detailed information on
medical treatment, chronic conditions, healthcare utilization, and expenditures. Medicare is the
US government mandated insurance program for about 97% of the US population aged 65 years
and above.45,46 The National Cancer institute (NCI) links SEER cases with Medicare enrolled
patients using an individual’s last name, first name, social security number, and date of birth.
More than 95% of the Medicare beneficiaries are enrolled in Medicare Part A and Part B
coverage. Medicare Part A reimburses the use of inpatient care in hospitals and skilled nursing
10

facilities, home health care, and hospice care. Part B covers the use of physician and outpatient
services. The Medicare beneficiaries enrolled in Health Maintenance Organizations (HMO) do
not have all the information in their medical claims because these organizations are not mandated
to submit all their service claims to the Center for Medicare and Medicaid (CMS). Hence, we
excluded those Medicare beneficiaries who were enrolled in HMO at any time during the study
period.
An encrypted identification number was provided for each Medicare beneficiary to link
the PEDSF file from SEER with the Medicare files. The Medicare data consisted of Medicare
Provider Analysis and Review (MEDPAR) files, the Carrier Claims (old name
Physician/Supplier National Claims History (NCH)), Outpatient, Home Health Agencies (HHA),
Hospice, Durable Medical Equipment (DME), and Part D Event (PDE). The MEDPAR file
includes Medicare Part A claims records and the NCH and outpatient files consist of Part B
claims for outpatient visits and physician services. Each claim record represents an episode of
health service use and includes up to 12 diagnoses according to the International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), service dates, and payments made
by the CMS. The carrier claims file includes the physician specialty associated with the service
provided. The carrier claims and outpatient claims files also include procedure codes according
to the Healthcare Common Procedure Coding System (HCPCS).
1.4.4 Area Health Resources File (AHRF)
The AHRF is a publicly available data file provided by the Department of Health and
Human Services which contains information on more than 6,000 variables for each of the US
counties.47 The AHRF contains data on the availability of health professionals, healthcare
facilities, and socioeconomic and environmental characteristics of each county. We used the state
11

and county Federal Information Processing Standard (FIPS) codes to link the AHRF files with
the SEER-Medicare dataset to measure the county level inter-personal, healthcare system, and
community factors.
1.5 Theoretical Framework
We utilized the Social Ecological Model (SEM) as the theoretical framework for this
study (Figure 1.1). We chose this model because patients’ visits to different provider specialties
and use of mammography and BDT are influenced by both their personal characteristics as well
as the surrounding social and organizational environments. Further, healthcare costs have been
found to be a result of expenditure decisions made at micro (age, sex, health status) and macro
(availability of hospitals, area poverty, area health insurance, travel time) levels.48 Hence, we
utilized a multilevel SEM to examine the costs of chronic conditions among Medicare
beneficiaries with DLBCL as compared to those without cancer.
The SEM is an overarching framework to investigate the interactions between diverse
personal and socio-physical factors that impact health behavior. The SEM provides a framework
to integrate multiple individual and contextual theories of health behavior and presents a more
comprehensive approach to study and modify particular behaviors.49 This theoretical perspective
will help us in examining the key personal and environmental factors that are significant
predictors of patients’ visits to a provider specialty and the receipt of preventive services.
According to the SEM, the following multiple levels influence a health behavior: (1)
intra-personal factors: personal characteristics such as socio-demographics, chronic conditions,
stage of cancer, and cancer treatments; (2) inter-personal factors: formal and informal social
support systems and networks made of family, friends, and colleagues (e.g., racial isolation index
and social or cultural cohesion); (3) Healthcare system factors: characteristics of healthcare
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system such as density of healthcare facilities and physicians; (4) community factors:
relationships among organizations within a larger political or geographical area, which can be
understood by SEER region, urban/rural region, area poverty and education, and; (5) public
policy: local, state, or federal policies and laws that support or inhibit certain health practices
such as policies and recommendations of IOM and USPSTF regarding the role of different
provider specialties in cancer care and recommendations for preventive services.50-52
There are five principles of SEM49: 1) Factors at multiple levels including intra-personal,
inter-personal, healthcare system, community, and policy factors influence health behaviors. The
relative effects of different factors vary with the particular behavior and context; 2) Contextual
factors including physical and social environments of the individual are important determinants
of health behavior; 3) Factors interact across multiple levels in modifying the health behavior.
Various individual and contextual factors work together in promoting or inhibiting a health
behavior; 4) Ecological models should be specific to the targeted behavior; and 5) Multilevel
interventions implement changes at individual, organizational, environmental, and policy levels
and hence, should be more effective than single level interventions.
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Figure 1.1 Social-Ecological Model of Health Behavior.
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1.6 Innovation of the Study
The visits to different provider specialties, receipt of preventive care, and the costs of
care for DLBCL patients is largely unknown. Most previous studies examining the visits to
different providers and preventive care have been conducted among patients with breast,
colorectal, or prostate cancer during the follow-up period. There is a lack of research on the visits
to PCPs, oncologists, and other medical specialists before cancer diagnosis, during cancer
treatment, and at follow-up periods among patients with DLBCL. Specifically, our study will
make the following novel contributions to literature:
1. Lack of evidence among patients with DLBCL. Most existing studies have evaluated visits
to different providers and receipt of mammography and BDT among patients with common
malignancies such as breast, colorectal, and prostate cancers.53-57 Forsythe and colleagues
conducted a survey among NHL patients after 2-5 years of cancer diagnosis.58 Many NHL
patients were found to visit oncologists, PCPs, and other medical specialists (46.6%), while
others saw only oncologists (12.9%), oncologists plus PCPs (24.6%), and oncologists plus other
medical specialists (15.9%) for cancer follow-up care in last one year.58 However, the study was
conducted in a small patient population (N = 363) in Los Angeles county. Further, the study by
Forsythe et al. utilized self-reports of visits to providers which may be affected by recall bias.
The study did not distinguish between the subtypes of NHL which have widely different
prognosis and require different treatments.1 Our study examined the provider visits and receipt of
preventive care by DLBCL patients, which is the most common subtype of NHL, by utilizing a
national claims database of elderly Medicare beneficiaries with cancer. DLBCL is an aggressive
form of cancer with unique treatments such as stem cell transplant. DLBCL can have a
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significant effect on the preventive care and costs, which is different from the effect of other
malignancies.
2. Investigation of visits to specialists other than PCPs. Most past studies have focused on the
roles of PCPs and oncologists only. A large proportion of cancer patients visit physicians of
other medical specialties such as cardiologists, pulmonologists, and endocrinologists.59 Our
study analyzed the visits to providers of all medical specialties at all the stages of cancer
treatment and follow-up.
3. Impact of cancer diagnosis on costs of chronic conditions. We could not find a study that
examined the change in costs of common chronic conditions during cancer diagnosis, treatment,
and follow-up periods. Our study examined the costs of chronic conditions and total costs of
DLBCL patients before diagnosis, during treatment, and at follow-up period to fill this gap in
literature.
4. Visits to provider specialties during cancer treatment period. Most extant studies have
examined the contact with physicians of different specialties and its effect on the outcomes of
care after the cancer treatment period is over. There is limited evidence on the involvement of
providers during the cancer treatment period. One study did not evaluate visits to physicians
during cancer treatment period with an assumption that visits to PCPs will decrease.42 However,
the IOM in its report on high quality cancer care, has emphasized the role of PCPs during the
cancer treatment period. In order to better understand the role of different provider specialties
during and after cancer treatment period, we examined the change in visits to physicians of
different specialties before, during, and after the cancer treatment period.
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5. Use of Social Ecological Model of health behavior. Visits to different provider specialties,
preventive services, and costs of care are affected by both the individual and environmental
factors. The factors at higher societal and community level such as the racial/ethnic composition,
availability of providers, and community education level have a significant effect on access to
care and healthcare utilization. A contextualized investigation of visits to and care received from
different provider specialties has been lacking in existing studies. We utilized the Social
Ecological Model of Health Behavior as the multilevel model to take into account the multiple
levels of factors in a systematic way.60
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Chapter 2: Impact of Diffuse Large B-Cell Lymphoma on Visits to Different Provider
Specialties among Elderly Medicare Beneficiaries: Challenges for Care Coordination
2.1 Abstract
Background. Newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL), a cancer with
vague symptomatology, can pose significant challenges to care-coordination. Objective. We
utilized a social-ecological model to understand the impact of DLBCL diagnosis on visits to
primary care providers (PCPs) and specialists, a key component of care-coordination, over a
three year period of cancer diagnosis and treatment. Methods. We used a retrospective
longitudinal study design with SEER-Medicare linked dataset to analyze visits to PCPs and
specialists by DLBCL patients (n=5,455) compared to non-cancer patients (n=14,770). Hurdle
models and multivariable logistic regression were used to examine number of PCP visits and any
visit to specialists, respectively. Results. DLBCL patients were more likely to visit PCPs (AOR
[95%CI]: 1.25 [1.18, 1.31]), and had greater number of visits to PCPs (β, SE: 0.384, -0.014) than
non-cancer patients. Further, DLBCL patients were more likely to have any visit to cardiologists
(AOR [95%CI]: 1.40 [1.32, 1.47]), endocrinologists (1.43, [1.21, 1.70]), and pulmonologists
(1.51 [1.36, 1.67]) than non-cancer patients. Among DLBCL patients, the number of PCP visits
markedly increased during the treatment period compared to the baseline period (β, SE: 0.491, 0.028) and then decreased to baseline levels (-0.464, -0.022). Conclusions. Visits to PCPs and
specialists were much higher for DLBCL than non-cancer patients, which drastically increased
during the DLBCL treatment period for chronic care. Treatment adverse effects and more
frequent contact with healthcare system may have increased the visits to PCPs and specialists.
Interventions to improve care-coordination may need to target the DLBCL treatment period,
when care-coordination is most vulnerable. Implications. Practice: DLBCL patients have higher
chronic care needs during the cancer treatment and follow-up periods and should be referred to
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suitable mental health specialists when necessary. Policy: Policymakers who want to improve
care-coordination for cancer patients may need to target the cancer treatment period. Research:
Future studies need to investigate the cancer patients’ perceived barriers to care-coordination
between their primary care providers, oncologists, and specialists.
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2.2 Introduction
Non-Hodgkin’s Lymphoma (NHL) is the most prevalent blood cancer with
approximately 72,580 new cases of NHL expected to be diagnosed in 2016.1 Diffuse Large Bcell Lymphoma (DLBCL) is the most common subtype of NHL and commonly occurs in adults
above 64 years of age.2 DLBCL can lead to secondary cancers,3 post-traumatic stress,4 and poor
quality of life in the elderly.5 Furthermore, 82.0% of elderly individuals have pre-existing
chronic physical or mental health conditions.6,7 Therefore, individuals diagnosed with DLBCL
receive care from multiple providers such as the oncologists, primary care physicians (PCPs),
and other medical specialists (e.g., cardiologist, endocrinologists, psychologists, and others).
Although not specific to DLBCL, elderly individuals visited an average of 6 different providers
in a year.8 Previous studies have found that under the fee-for-service system, such receipt of
uncoordinated care from multiple providers can lead to medication errors,9 duplication of
services,10 emergency room visits,11 unplanned hospital readmissions,12 costs,10,13 and
preventable hospitalizations13 and ultimately worsen the health outcomes of patients.14 In its
report on cancer survivorship, Institute of Medicine recommended that individualized
survivorship care plan should be developed to increase care coordination for cancer patients. The
U.S. Department of Health and Human Services15 and the National Quality Forum16 have also
developed strategic frameworks of care to identify novel models of care and include effective
care coordination as one of the care quality measures.
Care coordination may be further compromised with newly diagnosed cancer10 because
cancer patients need care from multiple providers for their chronic conditions as well as cancer.
For example, among breast cancer patients, visits to oncologists and PCPs increased after breast
cancer diagnosis.17-19 Colorectal cancer patients had more visits to PCPs after the treatment
period as compared to the pre-diagnosis period.20,21 These findings suggest that cancer patients
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may be receiving care from both oncologists and PCPs. However, DLBCL patients may consult
their PCPs or other medical specialists for symptoms, before being referred to an oncologist
because they may experience vague symptoms such as painless swelling of lymph nodes, fever,
and weight loss.22 The visits to PCPs and other medical specialists may continue during and after
the cancer treatment period because, unlike other cancers, DLBCL can affect multiple organs.23
In a cross-sectional survey conducted among NHL patients, 87.1% visited PCPs or other medical
specialists, in addition to their oncologists.24 However, the investigators did not examine
provider visits by patients with DLBCL which is markedly different in treatment and survival
prognosis from other subtypes of NHL.2 DLBCL is an aggressive form of NHL and is often
treated with intense therapeutic regimens such as stem cell transplant25,26 DLBCL treatment can
worsen other chronic conditions or patients may have new diagnosis of chronic conditions due to
increased contact with healthcare system. Therefore, the patterns of visits to PCPs and other
medical specialists may differ. It is also plausible that due to the prioritization of cancer care,
DLBCL patients may not continue to see their PCPs or other medical specialists after cancer
diagnosis, specifically during the cancer treatment period.27
To the best of our knowledge, no study has investigated whether DLBCL affects visits to
PCPs and other medical specialists, an indicator of care coordination. It is important to examine
DLBCL patients’ visits to PCPs and other medical specialists because cancer follow-up care in
primary care settings is cost-effective.28 Further, oncologists are responsible for the treatment of
cancer and may be less effective in providing care for other chronic conditions.29
2.3 Theoretical Framework
The primary objective of this study was to use the Social-Ecological model (SEM) to
evaluate the impact of newly diagnosed DLBCL on visits to PCPs and other medical specialist
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among the elderly Medicare beneficiaries compared to those without any cancer.30 The SEM is
an overarching framework to investigate diverse personal and socio-physical factors that impact
health behavior.30 We selected this framework because patients’ visits to providers can be
influenced by patients’ personal characteristics as well as external social and healthcare
environmental factors. These factors include: (a) intra-personal factors- patient’s sociodemographic characteristics, chronic conditions, and cancer treatments received; (b) interpersonal factors- county-level formal and informal social support systems c) healthcare system
factors: density of physicians and facilities; (d) community factors- SEER region, urbanacity,
area poverty and education.31-33 We used a nationally representative linked dataset of cancer
registries and Medicare claims in the United States. The secondary objective of this study was to
examine the change in PCP visits and use of medical specialists before and after DLBCL
diagnosis.
2.4 Methods
2.4.1 Study Design
We utilized a retrospective longitudinal design with 12-month pre-index and 24-month
post-index periods. For the DLBCL patients, pre- and post-index periods were identified using
the DLBCL diagnosis date as the index date. For the non-cancer patients, pre- and post-index
periods were derived using randomly selected dates of service from inpatient or outpatient
Medicare claims. The pre- and post-index period were divided into six equal time intervals of 6months each. For DLBCL patients, the pre-index period included baseline (t1) and pre-diagnosis
(t2) and post-index period comprised of treatment (t3), post-treatment (t4), short follow-up (t5),
and long follow-up (t6) periods.
2.4.2 Data Sources
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We linked data from several sources: 1) SEER cancer registries; 2) 5% Medicare sample
for patients without any cancer; 3) Medicare claims of SEER and non-cancer patients; and 4) the
Area Health Resource File (AHRF). The SEER is an epidemiologic surveillance system
consisting of data from 20 population-based tumor registries (Alaska Native Tumor Registry,
Arizona Indians, Cherokee Nation-Oklahoma, Connecticut, Detroit, Atlanta-Georgia, Greater
Georgia, Rural Georgia, San Francisco-Oakland, San Jose-Monterey, Greater California, Hawaii,
Iowa, Kentucky, Los Angeles, Louisiana, New Jersey, New Mexico, Seattle-Puget Sound, and
Utah).34 The SEER cancer registries collect information for all the newly diagnosed cancer cases
such as patient’s demographic characteristics, cancer site, date of cancer diagnosis, and cancer
pathology (e.g., stage and grade). Medicare claims can be linked to the SEER registries and
contain detailed information on medical treatment, chronic conditions, healthcare utilization, and
expenditures.
The AHRF is a publicly available data file provided by the Department of Health and
Human Services which contains information on more than 6,000 variables for each of the US
counties.35 The AHRF contains data on the availability of health professionals, healthcare
facilities, and socioeconomic and environmental characteristics of each county. We used the state
and county Federal Information Processing Standard (FIPS) codes to link the AHRF files with
the SEER-Medicare dataset to measure the county level inter-personal, healthcare system, and
community factors.
2.4.3 Study Population
The DLBCL was identified using the International Classification of Diseases for
Oncology - Third Revision (ICD-O-3)/World Health Organization 2008 codes: 13, 14, 15, 16)
during 2003-2011. The non-cancer patients were derived from a random 5% sample of Medicare
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beneficiaries who resided in SEER areas between 2003 and 2011 and were not diagnosed with
any cancer, except basal cell carcinoma. We selected a 10% random sample of non-cancer
patients.
The following exclusion criteria were applied to both DLBCL population and non-cancer
sample: (a) with missing values for any demographic factor (e.g., age, sex, race, region, and End
Stage Renal Disease (ESRD), (b) not alive during the observation period, (c) less than 66 years
of age, (d) having ESRD, (e) enrolled in managed care plans, (f) not continuously enrolled in
Medicare parts A and B during the pre- and post- index periods; and (g) not having any PCP visit
during the entire observation period (Appendix 2.1 and 2.2). Additional inclusion criteria were
applied to the DLBCL population: we included individuals if they had only one primary cancer
(except basal cell carcinoma) and if their cancer was not diagnosed from autopsy or death
certificate.
2.4.4 Measures
Dependent variables. The dependent variables for our study included any visit to PCPs
and other medical specialist. Further, we analyzed the number of PCP visits among those with at
least one PCP visit. These variables were measured every 180 days (i.e. t1 through t6) and were
derived from the National Claims History (NCH) files. The PCPs included general practice,
family practice, internal medicine, geriatric medicine, nurse practitioner, or physician assistant.36
Visits to other medical specialists were: (a) cardiologists among patients with any heart
condition; (b) endocrinologists among patients with diabetes; (c) mental health specialists
(psychologist or psychiatrist) among patients with depression and/or anxiety; and (d)
pulmonologists among patients with asthma or chronic obstructive pulmonary disease (COPD).
We identified the specialty of a physician by using the Health Care Financing Administration
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(HCFA) specialty codes. The HCFA specialty codes from the SEER-Medicare dataset have been
used in previous studies to examine the role of physician specialty in the care of breast and
colorectal cancer patients.36-38
Cancer Status Independent Variable. The key independent variable was the presence
of DLBCL vs. no cancer, which belonged to the domain of intra-personal factors as per SEM.
SEM Independent Variables. The independent variables in our study included both time
varying and time invariant variables. The time varying factors included chronic conditions of
arthritis, diabetes, any heart condition, any mental condition, and any respiratory condition and
DLBCL treatments of chemotherapy, radiotherapy, and immunotherapy (only for those
diagnosed with DLBCL). The time varying factors were measured repeatedly during each time
interval from t1 to t6. All other intra-personal, inter-personal, healthcare, and community factors
were time invariant and were measured during one year before the index date.
Intra-personal factors. (a) age at index date (66-69, 70-74, 75-79, or >=80 yrs.); (b) sex
(male or female); (c) race (Non-Hispanic White, Non-Hispanic African American, Hispanic, or
others); (d) geographic region (Northeast, South, North-Central, or West); (e) rural/urban (metro,
urban, or rural); (f) arthritis (osteoarthritis or rheumatoid arthritis); (g) diabetes; (h) any heart
condition (cardiac arrhythmia, coronary artery disease, or congestive heart failure); (i) depression
or anxiety; (j) respiratory condition (Asthma or COPD); (k) DLBCL stage from the Ann Arbor
staging system (stage I, II, III or IV); (l) chemotherapy; (m) radiotherapy; (n) immunotherapy;
and (o) stem cell transplant.
Inter-personal factors. Inter-personal factors included county-level racial/ethnic
isolation measured by: (a) percentage of Blacks; (b) percentage of Hispanics; and (c) social or
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cultural cohesion measured by percentage of non-English speaking individuals above 18 years of
age.
Healthcare system factors. Healthcare system factors were measured at the county
level. These factors included: (a) health professional shortage area for PCPs (whole county, part
of county, or no shortage); (b) quartiles of average number of hospitals per 10,000 elderly
individuals above 65 years of age (0.56, 0.97, 1.31, 3.46); and (c) quartiles of average number of
Federal Qualified Health Centers (FQHC) per 10,000 elderly individuals above 65 years of age
(0.01, 0.37, 0.94, 3.68).
Community factors. Community factors included: (a) county percentage of individuals
between 18 and 64 years of age without health insurance quartiles (13.10, 17.70, 22.57, 28.72);
(b) county average travel time to work quartiles (19.73, 24.19, 27.44, 30.95); and (c) county
percentage of individuals with below high school education quartiles (8.44, 12.27, 16.31, 25.01).
In addition to the variables guided by SEM, we also included time and index year as covariates
in all the models.
2.4.5 Statistical Analyses
We used chi-square tests to analyze the model-driven differences in intra-personal, interpersonal, healthcare system, and community factors between DLBCL and the non-cancer
patients. As repeated observations were made for PCP visits from t1 to t6, each subject was
clustered over time. As each person had 6 observations, the observations were dependent and to
account for the non-independence of observations, we used the unstructured correlation
structure. We used hurdle models to analyze any visit to PCPs and the number of PCP visits. A
hurdle model analyzes the two processes of generating zeroes and positive values separately.39
The first part of the model, known as ‘hurdle at zero’, analyzes the occurrence of an outcome
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(i.e., PCP visit or no visit). The second part of the model, known as ‘above the hurdle’, analyzes
the positive values of the outcome (i.e., number of PCP visits above zero).40 Population-averaged
logistic regression models (also known as Generalized Estimating Equations -GEE) were used to
analyze the relationship between DLBCL and visit to providers.40 All analyses were conducted
using STATA version 14.41 Our preliminary analysis indicated that there were significant
differences in characteristics between the DLBCL and non-cancer patients. To reduce this
observed selection bias between the DLBCL and non-cancer patients, we derived Inverse
Probability Treatment Weights (IPTW) by conducting a logistic regression on DLBCL vs no
cancer with the following independent variables: sex, race/ethnicity, age, index year, and chronic
conditions. Results from the logistic regression are presented in Appendix 2.3. These IPTWs
were used as weights in all the unadjusted and adjusted analyses.
2.5 Results
2.5.1 Description of DLBCL and Non-Cancer Patient Characteristics
Table 2.1 summarizes the selected characteristics of DLBCL and non-cancer patients
before and after adjustments with IPTW. Before adjusting for observed selection bias with
IPTW, DLBCL patients had higher percentage of males, whites, and above 75 years of age as
compared to those with no cancer.
2.5.2 Hurdle Model: Impact of DLBCL on Any Visit to PCP and Number of PCP Visits
A higher proportion of DLBCL patients visited PCPs as compared to non-cancer patients
(t1: 75.3% vs 75.1%; t2: 84.1% vs 75.5%; t3: 92.3% vs 82.2%; t4: 81.4% vs 75.7%; t5: 80.5% vs
77.3%; t6: 81.0% vs 77.9%). Figure 2.1 displays the differences in any visit to PCP between
DLBCL patients and those without cancer from t1 to t6. Figure 2.2 summarizes the differences in
the predicted number of PCP visits between the DLBCL and non-cancer patients. Without any
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adjustments for chronic conditions, the number of visits to PCP were higher among those with
DLBCL compared to the non-cancer patients (t1: 3.57 vs 3.46; t2: 4.29 vs 3.44; t3: 8.36 vs 3.55;
t4: 5.12 vs 3.61; t5: 4.41 vs 3.63; t6: 4.50 vs 3.82). After adjusting for the presence of chronic
conditions at each time period, DLBCL patients still had higher number of PCP visits (predicted)
compared to non-cancer patients (t1: 5.00 vs 3.27; t2: 4.86 vs 3.42; t3: 5.28 vs 3.45; t4: 4.99 vs
3.53; t5: 4.73 vs 3.53; t6: 4.48 vs 3.54).
Table 2.2 summarizes the parameter estimates from the unadjusted and adjusted hurdle
models of any visit to PCP and the number PCP visits. After adjusting for all SEM independent
variables, DLBCL patients were more likely to visit PCPs (AOR = 1.25, 95% CI = [1.18, 1.31])
and had more PCP visits (beta = 0.384, SE = -0.014) than non-cancer patients.
2.5.3 SEM Independent Variables and Any Visit to PCP and Number of PCP Visits
Females, older individuals, other racial minorities (vs Whites), those living in South or
North-Central compared to North-East, arthritis patients, heart disease patients, respiratory
condition patients, mental health condition patients, and diabetes patients were more likely to
visit PCPs and had higher number of PCP visits. Those living in counties with more hospitals
and higher average travel time were less likely to have any PCP visit and had fewer PCP visits
(Appendix 2.4).
2.5.4 Impact of DLBCL on Any Visit to Other Medical Specialists
Figure 2.1 displays the differences in any visit to other medical specialists between
DLBCL patients and those without cancer from t1 to t6. With regard to other medical specialties,
a higher percentage of DLBCL patients visited cardiologists (t1: 70.2% vs 64.5%; t2: 62.8% vs
54.9%; t3: 83.7% vs 51.9%; t4: 50.7% vs 46.4%; t5: 46.0% vs 45.3%; t6: 46.6% vs 44.6%),
endocrinologists (t1: 7.6% vs 6.1%; t2: 7.0% vs 5.3%; t3: 8.8% vs 5.1%; t4: 6.6% vs 4.7%; t5:

36

6.0% vs 4.5%; t6: 6.1% vs. 4.8%), pulmonologists (t1: 25.8% vs 22.6%; t2: 23.7% vs 17.7%; t3:
34.1% vs 15.2%; t4: 18.5% vs 13.3%; t5: 15.2% vs 12.8%; t6: 14.0% vs 12.1%), and
rheumatologists (t1: 18.1% vs 11.0%; t2: 14.3% vs 7.9%; t3: 8.7% vs 7.5%; t4: 7.4% vs 6.3%;
t5: 7.1% vs 6.1%; t6: 6.7% vs 5.6%) as compared to non-cancer patients. However, with regard
to mental health specialists, we did not observe a clear pattern of use among DLBCL patients (t1:
34.9% vs 31.1%; t2: 30.6% vs 33.9%; t3: 31.7% vs 30.6%; t4: 36.7% vs 33.9%; t5: 32.2% vs
35.6%; t6: 37.1% vs 32.6%). DLBCL patients were more likely to visit cardiologists (AOR =
1.40, 95%CI = [1.32, 1.47]), endocrinologists (1.43 [1.21, 1.70]), and pulmonologists (1.50
[1.36, 1.67]) than patients with no cancer from both unadjusted and adjusted models (Table 2.3).
2.5.5 SEM Independent Variables and Any Visit to Other Medical Specialties
Those with arthritis, asthma, mental health condition, or diabetes were more likely to
have any visit to cardiologists. The elderly with any heart condition or mental health condition
were more likely to have any visit to endocrinologists. The elderly with any heart condition,
mental health condition, or diabetes were more likely to have any visit to pulmonologists.
Further, females, other races, those living in North-Central or West region, and rural areas were
less likely to have any visit to cardiologists and pulmonologists (Appendix 2.5).
2.5.6 Change in Number of PCP visits over Time among DLBCL Patients
The results from the adjusted negative binomial regressions for number of PCP visits
among beneficiaries with DLBCL are displayed in Table 2.4. When baseline period (t2) was
used as the reference group, we observed that the number of PCP visits increased during prediagnosis (t1) and treatment (t3) periods and decreased during the follow-up periods (t5, t6).
When treatment period (t3) was used as the reference group, the number of visits during
baseline, pre-diagnosis, post-treatment, and follow-up periods were significantly lower.
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2.5.7 SEM Independent Variables and Number of PCP Visits among DLBCL Patients
Intra-personal factors associated with higher number of visits to PCPs among DLBCL
patients included greater age, female sex, South, North-Central, or West region compared to
North-East, arthritis, diabetes, any heart condition, depression or anxiety, and asthma or COPD
(Appendix 2.6). With respect to DLBCL treatments, those receiving radiotherapy and
immunotherapy had more PCP visits while those receiving stem cell transplants had less PCP
visits. The inter-personal factors positively associated with lower number of PCP visits included
living in counties with a higher percentage of Blacks. With respect to community factors, those
living in counties with lower number of individuals with health insurance had lower PCP visits,
and those living in counties with lower education level had higher PCP visits.
2.6 Discussion
In this first study of its kind, we examined the impact of newly diagnosed DLBCL on
visits to different provider specialties to understand the challenges for care-coordination. We
analyzed the impact of DLBCL on any PCP visit, number of PCP visits, and any visit to other
medical specialists by using a robust study design that compared DLBCL patients with cancerfree patients. Our study findings indicated that DLBCL patients were more likely to visit PCPs
and had higher number of PCP visits as compared to those without any cancer, even after
adjusting for intra-personal, inter-personal, healthcare system, and community factors. These
findings are consistent with a previous study in breast cancer patients who had higher PCP visits
than non-cancer patients.17
Further, we found that DLBCL patients were more likely to visit other medical specialists
as compared to non-cancer patients. This is a unique finding because none of the published
studies examined the relationship between cancer diagnosis and visits to other medical
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specialists, a key indicator of care coordination. This finding suggests problems for care
coordination for patients enrolled in fee-for-service Medicare, because Medicare does not
compensate the providers for communicating with other providers for care coordination.
Providers have to face many challenges even with the availability of electronic health records
due to a lack of interoperability between electronic health information systems.42
With respect to change in PCP visits, our study findings are somewhat consistent with
previous studies in colorectal and breast cancer patients, who were found to increase in their
visits to PCP during the post-treatment period (i.e. one year after cancer diagnosis).17-20 Our
study results indicated that the PCP visits increased three fold during the treatment period. One
possible explanation for more visits to PCPs and other medical specialists among DLBCL
patients is the presence of multiple chronic conditions. We observed that DLBCL patients had
higher prevalence of diabetes, arthritis, any heart condition, depression or anxiety, and asthma or
COPD than non-cancer patients. Our findings also indicated that many patients were newly
diagnosed with chronic conditions after DLBCL diagnosis and treatment, which statistically
explained the variations in number of PCP visits over time. These findings suggest that visits to
PCPs and other medical specialists may be greater among DLBCL patients due to higher
prevalence and incidence of chronic conditions, which can complicate the management of cooccurring chronic conditions and cancer. Further, the chemotherapy and stem cell transplant are
associated with significant adverse effects such as cardiotoxicity43 and loss of bone density.44
These adverse effects may be another reason for the increase in visits to specialists during the
treatment period. This sharp increase in provider visits poses significant challenges to care
coordination. DLBCL patients may face greater difficulties in care coordination because the
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roles of PCPs and other medical specialists have not been properly defined during the cancer
treatment period.45,46
Surprisingly, we did not find a significant difference in visits to mental health providers
among elderly patients with both DLBCL and mental health conditions as compared to those
without any cancer, after adjusting for time, index year, and other SEM factors. As the diagnosis
and treatment of DLBCL leads to significant long term psychiatric morbidity such as anxiety,
depression, post-traumatic stress disorder, and lower health status,47-49 it is concerning that
DLBCL patients’ visits to mental health providers did not change. PCPs and oncologists may
need to be more aware that the elderly DLBCL patients with pre-existing mental health
conditions are highly susceptible to further mental health deterioration and should refer such
patients to suitable mental health providers when necessary.
Future studies need to investigate whether the strategic frameworks developed by the
U.S. Department of Health and Human Services15 and the National Quality Forum16 can be
implemented in the context of cancer care and can improve care-coordination for elderly patients
with cancer and multiple chronic conditions. Another measure for improving the carecoordination between oncologists and PCPs is the use of survivorship care plans. In response to
the Institute of Medicine’s report on cancer survivorship, many groups have developed specific
care plans for cancer patients.50 These care plans may be helpful in improving the coordination
of care between providers during and after the treatment period.51
Our study findings should be interpreted in the context of some limitations. We used the
HCFA provider specialty codes given in the Physician/Supplier Claims file (NCH) of the SEERMedicare dataset to identify the provider specialties in this study. Although the HCFA codes
have been used in previous studies on elderly cancer patients,36,52,53 these codes may not capture
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all the visits to different provider specialties.54 The purpose of our study was to examine the
burden and opportunities for care coordination during the different phases of care among elderly
patients with DLBCL. We did not investigate the actual provider-provider interaction or patients’
and providers’ experiences of care coordination in this study. Our study results can be
generalized to Medicare fee-for-service beneficiaries who resided in SEER regions only.
The strengths of our study include the use of SEER-Medicare database, which is a
nationally representative data to examine the care of elderly patients with newly diagnosed
cancer. We examined the visits to other medical specialists over a three year time period
spanning the cancer diagnosis, treatment, and follow-up periods which had not been analyzed
before. We used a comprehensive SEM framework to examine the association of various
personal and contextual factors with the visits to different provider specialties among elderly
DLBCL patients. Further, we utilized a robust study design with a non-cancer comparison group
and time varying diagnosis of chronic conditions in our study.
2.7 Conclusions
The elderly Medicare beneficiaries with DLBCL were more likely to visit PCPs or other
medical specialists and had higher number of visits to PCPs compared to non-cancer patients.
The treatment adverse effects and more frequent contact with healthcare system may have led to
increased diagnosis of other chronic conditions, which partially explained the higher visits to
PCPs and specialists. The time period immediately after DLBCL diagnosis need to be targeted to
implement interventions to improve care coordination between the oncologist, PCP, and other
medical specialists.
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Table 2.1 Description of Selected Characteristics of Elderly Medicare Beneficiaries with Diffuse Large
B-Cell Lymphoma (DLBCL) and Non-Cancer Patients before and after Inverse Probability Treatment
Weights. Surveillance Epidemiology and End Results Program (SEER) - Medicare 2003-2011.
DLBCL
Non-Cancer
DLBCL
Non-Cancer
N
%
N
%
Sig. Col. wt %
Col. wt %
All
Age (Years)
66-69
70-74
75-79
>=80
Sex
Female
Male
Race/Ethnicity
White
African American
Hispanic
Others
Geographic region
Northeast
South
North-central
West
Rural/Urban
Metro
Urban
Rural

5455

27.0
14,770
73.0
Intra-Personal Factors

27.0

73.0

27.3
26.4
20.6
25.7

27.3
26.2
20.6
25.9

62.2
37.8

61.9
38.1

82.1
7.2
2.5
8.1

82.5
7.0
2.5
8.1

19.5
25.6
11.9
43.0

20.0
24.8
12.1
43.2

19.8
25.0
12.2
43.1

12,172
82.4
2,278
15.4
320
2.2
Other Factor

83.3
14.7
2.0

82.3
15.5
2.2

***
1,071
1,374
1,373
1,637

19.6
25.2
25.2
30.0

4,452
3,914
2,786
3,618

30.1
26.5
18.9
24.5
***

3,029
2,426

55.5
44.5

9,479
5,291

64.2
35.8
***

4,796
190
120
349

87.9
3.5
2.2
6.4

11,885
1,217
379
1,289

80.5
8.2
2.6
8.7
***

1,113
1,267
720
2,355

20.4
23.2
13.2
43.2

4,525
815
115

83.0
14.9
2.1

2,885
3,779
1,752
6,354

Index year
***
2003
584
10.7
1,255
8.5
9.0
9.1
2004
589
10.8
1,349
9.1
9.8
9.6
2005
586
10.7
1,280
8.7
9.4
9.3
2006
584
10.7
1,432
9.7
10.3
10.0
2007
610
11.2
1,569
10.6
10.7
10.8
2008
609
11.2
1,653
11.2
11.3
11.2
2009
623
11.4
1,888
12.8
12.3
12.4
2010
624
11.4
2,052
13.9
13.1
13.2
2011
646
11.8
2,292
15.5
14.2
14.5
Note. Based on 5,455 Medicare beneficiaries with Diffuse Large B-Cell Lymphoma and a random sample of 14,770
beneficiaries without any cancer who resided in SEER areas. Weighted percentages were derived with using inverse
probability treatment weights.
Sig.: significance level; wt: Weighted
*** p < .001
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Table 2.2 Unadjusted and Adjusted Parameter Estimates of DLBCL vs No Cancer from Hurdle Models on Any Visit to PCP and
Number of PCP Visits with Inverse Probability Treatment Weights. Surveillance Epidemiology and End Results Program (SEER)Medicare 2003-2011.
Any PCP Visit
Number of PCP Visits
DLBCL

Time

DLBCL

Time

DLBCL*Time

OR

95% CI

OR

95% CI

β

SE

β

SE

β

SE

Model 1

1.388***

[1.317, 1.463]

1.034***

[1.026, 1.042]

0.428***

-0.015

0.016***

-0.002

-0.050***

-0.004

Model 2

1.386***

[1.316, 1.461]

1.034***

[1.026, 1.042]

0.439***

-0.015

0.016***

-0.002

-0.052***

-0.004

Model 3

1.243***

[1.179, 1.309]

0.950***

[0.941, 0.958]

0.382***

-0.014

-0.034***

-0.002

-0.050***

-0.004

Model 4 1.245*** [1.182, 1.312] 0.948*** [0.940, 0.957] 0.384*** -0.014 -0.034*** -0.002 -0.049***
Note. Model 1: Unadjusted; Model 2: Adjusted for age, sex, race, region, rural/urban, index year; Model 3: Adjusted for
age, sex, race, region, rural/urban, index year, arthritis, diabetes, heart conditions, depression/anxiety, asthma/chronic
obstructive pulmonary disease; Model 4: Adjusted for age, sex, race, region, rural/urban, arthritis, diabetes, any heart
condition, depression/anxiety, asthma/chronic obstructive pulmonary disease, county% black, county% hospitals, county%
without health insurance, county average travel time, and county% below high school education.
Based on 5,455 Medicare beneficiaries with Diffuse Large B-Cell Lymphoma and 19,215 beneficiaries without any cancer
who resided in SEER areas. OR: Odds Ratios; CI: Confidence intervals; DLBCL: Diffuse Large B-Cell Lymphoma; SE:
Standard errors.
*** p <.001

-0.004
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Table 2.3 Unadjusted and Adjusted Estimates from Logistic Regression with Generalized Estimating
Equation on Any Visit to Other Medical Specialists with Inverse Probability Treatment Weights.
Surveillance Epidemiology and End Results Program (SEER)-Medicare 2003-2011.
Cardiologist
Endocrinologist
Pulmonologist
OR
95% CI
OR
95% CI
OR
95% CI
Model 1
DLBCL
1.409*** [1.336, 1.485]
1.485*** [1.250, 1.764] 1.578***
[1.423, 1.749]
Time
0.940*** [0.932, 0.948]
1.024
[1.000, 1.050] 0.936***
[0.919, 0.953]
Model 2
DLBCL
1.396*** [1.324, 1.472]
1.431*** [1.206, 1.696] 1.505***
[1.358, 1.667]
Time
0.923*** [0.914, 0.932]
1.008
[0.981, 1.035] 0.906***
[0.889, 0.925]
Note. Model 1: Unadjusted; Model 2: Adjusted for age, sex, race, region, rural/urban, arthritis, diabetes, any heart
condition, depression/anxiety, asthma/chronic obstructive pulmonary disease, county% black, county% hospitals,
county average travel time, county% without health insurance, and county% below high school education. Any visit
to other medical specialist was analyzed only among those with the corresponding chronic condition (e.g., any visit
to endocrinologists was analyzed among those with diabetes).
CI: Confidence intervals; OR: Odds ratios.
*** p <.001
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Table 2.4 Unadjusted and Adjusted Estimates from Negative Binomial Regressions with
Generalized Estimating Equation on Number of Visits to Primary Care Physicians (PCPs) among
elderly with Diffuse Large B-Cell Lymphoma (DLBCL). Surveillance Epidemiology and End
Results Program (SEER)-Medicare 2003-2011.
Model 1
β

Model 2
SE

β

Model 3
SE

β

SE

-0.491***

-0.0284
-0.028

Time
Baseline, t1

Ref.

Ref.

Pre-diagnosis, t2

0.201***

-0.017

0.134***

-0.016

Treatment, t3

0.872***

-0.020

0.491***

-0.028

-0.357***
Ref.

Post-treatment, t4

0.337***

-0.020

0.027

-0.022

-0.464***

-0.022

Short follow-up, t5

0.188***

-0.020

-0.121***

-0.020

-0.612***

-0.026

Long follow-up, t6

0.220***
-0.020 -0.108***
-0.022 -0.599***
-0.027
Note. Model 1: Unadjusted; Model 2&3:Adjusted for age, sex, race, region, rural/urban, marital status, arthritis,
diabetes, any heart condition, depression/anxiety, asthma/chronic obstructive pulmonary disease, DLBCL stage,
radiotherapy, chemotherapy, immunotherapy, stem cell transplant, county% black, county% hospitals, county%
without health insurance, and county% below high school education.
SE: Standard errors.
**.05< p < .01, ***.01< p <.001
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Figure 2.1 Differences in Any Visit to Primary Care Physician and Other Medical Specialists between Elderly
Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma and No Cancer. SEER Medicare 2003-2011.

Note: Based on the differences in percentages of patients with any visit to provider between DLBCL and non-cancer
patients for each time point.
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Figure 2.2 Unadjusted and Adjusted Differences in Average Number of Visits to Primary Care Physicians between
Elderly Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma and No Cancer. SEER Medicare 2003-2011.

Note. Calculated among those with at least one primary care physician visit.
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Appendix 2.1 Flowchart of Sample Selection for Elderly Medicare Beneficiaries with Diffuse Large B-Cell
Lymphoma.
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Appendix 2.2 Flowchart of Sample Selection for Elderly Medicare Beneficiaries with No Cancer.

.
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Appendix 2.3 Adjusted Estimates from Logistic Regressions on
Diffuse Large B-Cell Lymphoma vs. No Cancer by Selected
Characteristics of Elderly Medicare Beneficiaries. Surveillance
Epidemiology and End Results Program (SEER)-Medicare 2003-2011.
AOR
95% CI
Sig.
Sex
Female
0.66
[0.62, 0.70] ***
Male
Ref.
Age
70-74
1.40
[1.28, 1.54] ***
75-79
1.92
[1.74, 2.11] ***
>=80
1.81
[1.65, 1.99] ***
66-69
Ref.
Race
African American 0.41
[0.35, 0.49] ***
Hispanic
0.73
[0.59, 0.91] **
Others
0.66
[0.58, 0.75] ***
White
Ref.
Index Year
2003
Ref.
2004
0.94
[0.81, 1.08]
2005
0.96
[0.83, 1.10]
2006
0.85
[0.74, 0.98] *
2007
0.81
[0.71, 0.93] **
2008
0.78
[0.68, 0.89] ***
2009
0.70
[0.61, 0.81] ***
2010
0.66
[0.58, 0.76] ***
2011
0.62
[0.54, 0.71] ***
Region
South
0.95
[0.86, 1.04]
North-central
1.07
[0.95, 1.20]
West
1.03
[0.94, 1.12]
North East
Ref.
Baseline arthritis
Yes
1.20
[1.12, 1.29] ***
No
Ref.
Baseline any heart condition
Yes
1.23
[1.15, 1.32] ***
No
Ref.
Baseline diabetes
Yes
1.06
[0.99, 1.14]
No
Ref.
Baseline asthma or COPD
Yes
1.08
[1.00, 1.17]
No
Ref.
Note. Based on 5,455 Medicare beneficiaries with Diffuse Large B-Cell Lymphoma and 14,770 beneficiaries
without any cancer who resided in SEER areas. AOR: Adjusted odds ratios; COPD: Chronic Obstructive Pulmonary
Disease; Sig. significance.
***p<.001 **.001<p<.01 *p<.05
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Appendix 2.4 Adjusted Parameter Estimates from Hurdle Models on Any Visit to PCP and
Number of PCP Visits with Inverse Probability Treatment Weights. Surveillance
Epidemiology and End Results Program (SEER) Medicare 2003-2011.
Any Visit to PCP
AOR
95% CI

Number of PCP Visits
β
SE

DLBCL
Yes
No Cancer

1.245***
Ref.

[1.182,1.312]

0.384***
Ref.
-0.034***

-0.014

0.948***

[0.940,0.957]

NA

NA

-0.049***

-0.004

Female
Male

1.382***
Ref.

[1.322,1.446]

0.067***
Ref.

-0.010

70-74
75-79
>=80
66-69

1.113***
1.169***
1.308***
Ref.

[1.052,1.178]
[1.097,1.245]
[1.230,1.390]

0.039**
0.065***
0.145***
Ref.

-0.013
-0.015
-0.013

African American
Hispanic
Others
White

0.893*
0.742***
1.243***
Ref.

[0.812,0.982]
[0.647,0.850]
[1.134,1.363]

0.012
0.038
0.077***
Ref.

-0.018
-0.028
-0.021

South
North-Central
West
North East

1.553***
1.071
1.058
Ref.

[1.422,1.697]
[0.980,1.171]
[0.977,1.145]

0.072***
0.111***
0.069***
Ref.

-0.018
-0.018
-0.017

Rural
Urban
Metro

0.858***
0.734***
Ref.

[0.795,0.925]
[0.622,0.866]

0.016
0.012
Ref.

-0.016
-0.034

Yes
No

1.567***
Ref.

[1.501,1.636]

0.190***
Ref.

-0.009

Yes
No

1.508***
Ref.

[1.446,1.573]

0.333***
Ref.

-0.010

Yes
No

1.464***
Ref.

[1.391,1.540]

0.227***
Ref.

-0.011

Yes
No

2.233***
Ref.

[2.076,2.403]

0.333***
Ref.

-0.013

Yes
No

1.824***
Ref.

[1.741,1.911]

0.202***
Ref.

-0.010

1.26

Ref.

Time
DLBCL*Time
Sex

-0.002

Age (Years)

Race

Region

Rural/Urban

Arthritis

Any heart condition

Asthma or COPD

Depression/anxiety

Diabetes

County% Blacks
Ref.
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Appendix 2.4 Adjusted Parameter Estimates from Hurdle Models on Any Visit to PCP and
Number of PCP Visits with Inverse Probability Treatment Weights. Surveillance
Epidemiology and End Results Program (SEER) Medicare 2003-2011.
4.51
9.85
30.52

0.922*
0.960
0.970

[0.861,0.988]
[0.886,1.041]
[0.887,1.061]

-0.026
0.006
-0.044*

-0.015
-0.017
-0.018

County% Hospitals
0.56
Ref.
Ref.
0.97
1.035
[0.967,1.107]
0.012
-0.016
1.31
1.005
[0.938,1.076]
-0.009
-0.015
3.46
0.900*
[0.829,0.976]
-0.039*
-0.017
County% without health insurance
13.10
Ref.
Ref.
17.70
0.920*
[0.853,0.992]
0.001
-0.015
22.57
0.751***
[0.687,0.822]
-0.020
-0.018
28.72
0.782***
[0.706,0.865]
-0.031
-0.020
County average travel time
19.73
Ref.
Ref.
24.19
0.968
[0.905,1.035]
-0.038**
-0.014
27.44
0.902**
[0.839,0.970]
-0.018
-0.015
30.95
0.827***
[0.764,0.894]
-0.061***
-0.016
County% less than high school
education
8.44
Ref.
Ref.
12.27
0.978
[0.912,1.049]
0.005
-0.014
16.31
1.03
[0.952,1.116]
0.042**
-0.016
25.01
1.032
[0.943,1.130]
0.081***
-0.018
Note. Based on 5,455 Medicare beneficiaries with Diffuse Large B-Cell Lymphoma (DLBCL) and 14,770
beneficiaries without any cancer who resided in SEER areas. Adjusted beta coefficients and standard errors are from
Generalized Estimating Equation with negative binomial distribution and unstructured correlation matrix. AOR:
Adjusted odds ratios; CI: Confidence interval; COPD: Chronic Obstructive Pulmonary Disease; PCP: Primary Care
Physician; Sig. significance.
***p<.001 **.001<p<.01 *p<.05
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Appendix 2.5 Adjusted Parameter Estimates from Logistic Regression with Generalized Estimating Equations on
Any Visit to Other Medical Specialists with Inverse Probability Treatment Weights. Surveillance Epidemiology and
End Results Program (SEER) Medicare 2003-2011.
Cardiologists

Endocrinologists

Pulmonologists

AOR

95% CI

AOR

95% CI

AOR

95% CI

1.396***
Ref.

[1.324, 1.472]

1.431***
Ref.

[1.206, 1.696]

1.505***
Ref.

[1.358, 1.667]

0.923***

[0.914, 0.932]

1.008

[0.981, 1.035]

0.906***

[0.889, 0.925]

Female
Male

0.748***
Ref.

[0.707, 0.791]

1.104
Ref.

[0.928, 1.314]

0.888*
Ref.

[0.798, 0.988]

70-74
75-79
>=80
66-69

1.086*
1.162***
1.190***
Ref.

[1.007, 1.170]
[1.074, 1.258]
[1.105, 1.282]

1.028
0.825
0.638***
Ref.

[0.827, 1.276]
[0.650, 1.047]
[0.500, 0.815]

1.012
1.136
0.869
Ref.

[0.874, 1.172]
[0.974, 1.325]
[0.748, 1.010]

African
American
Hispanic
Others
White

0.765***
0.880
0.818***
Ref.

[0.686, 0.852]
[0.743, 1.042]
[0.737, 0.907]

0.9
0.582
0.808
Ref.

[0.644, 1.258]
[0.317, 1.067]
[0.599, 1.091]

0.965
0.822
0.815
Ref.

[0.769, 1.211]
[0.589, 1.147]
[0.654, 1.016]

1.062
0.827***
0.777***
Ref.

[0.954, 1.181]
[0.744, 0.919]
[0.706, 0.855]

0.599**
0.489***
0.619***
Ref.

[0.439, 0.819]
[0.356, 0.672]
[0.478, 0.802]

0.955
0.835
0.825*
Ref.

[0.778, 1.172]
[0.682, 1.023]
[0.686, 0.992]

0.803***
0.747**
Ref.

[0.728, 0.887]
[0.611, 0.912]

0.724
0.640
Ref.

[0.496, 1.056]
[0.286, 1.430]

0.766*
0.777
Ref.

[0.624, 0.941]
[0.522, 1.155]

1.089***
Ref.

[1.039, 1.141]

1.019
Ref.

[0.887, 1.170]

1.036
Ref.

[0.941, 1.139]

1.310***
Ref.

[1.141, 1.504]

1.620***
Ref.

[1.451, 1.807]

DLBCL
Yes
No Cancer
Time
Sex

Age (Years)

Race

Region
South
North-Central
West
North East
Rural/Urban
Rural
Urban
Metro
Arthritis
Yes
No
Any heart condition
Yes
No
Asthma or COPD
Yes
No
Depression/anxiety
Yes
No
Diabetes
Yes
No
County% Blacks
1.26
4.51

NA

1.184***
Ref.

[1.128, 1.243]

0.975
Ref.

[0.839, 1.133]

NA

1.390***
Ref.

[1.313, 1.472]

1.226**
Ref.

[1.077, 1.396]

1.312***
Ref.

[1.193, 1.444]

1.172***
Ref.

[1.118, 1.229]

NA

1.109*
Ref.

[1.009, 1.218]

[0.876, 1.045]

Ref.
1.161

Ref.
1.164

Ref.
0.957
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[0.872, 1.546]

[0.973, 1.394]

Appendix 2.5 Adjusted Parameter Estimates from Logistic Regression with Generalized Estimating Equations on
Any Visit to Other Medical Specialists with Inverse Probability Treatment Weights. Surveillance Epidemiology and
End Results Program (SEER) Medicare 2003-2011.
9.85
0.965
[0.875, 1.065] 1.212
[0.881, 1.668] 1.253*
[1.032, 1.522]
30.52
0.978
[0.877, 1.089] 1.345
[0.947, 1.910] 1.172
[0.954, 1.440]
County% Hospitals
0.56
Ref.
Ref.
Ref.
0.97
0.953
[0.877, 1.035] 0.916
[0.725, 1.156] 0.955
[0.814, 1.122]
1.31
0.942
[0.866, 1.026] 0.762*
[0.592, 0.982] 0.984
[0.832, 1.164]
3.46
0.940
[0.847, 1.042] 0.772
[0.530, 1.124] 0.881
[0.712, 1.091]
County% without health
insurance
13.10
Ref.
Ref.
Ref.
17.70
0.968
[0.883, 1.061] 1.117
[0.859, 1.451] 1.021
[0.859, 1.214]
22.57
1.000
[0.896, 1.115] 1.541*
[1.106, 2.148] 0.955
[0.776, 1.176]
28.72
0.945
[0.834, 1.070] 1.356
[0.935, 1.966] 0.946
[0.747, 1.199]
County average travel time
19.73
Ref.
Ref.
Ref.
24.19
1.042
[0.957, 1.134] 1.165
[0.867, 1.566] 0.920
[0.776, 1.089]
27.44
1.054
[0.964, 1.152] 1.391*
[1.031, 1.877] 1.006
[0.844, 1.198]
30.95
1.129*
[1.025, 1.244] 1.595**
[1.181, 2.155] 1.051
[0.870, 1.271]
County% less than high
school education
8.44
Ref.
Ref.
Ref.
12.27
0.987
[0.904, 1.077] 0.804
[0.618, 1.047] 0.928
[0.782, 1.101]
16.31
0.987
[0.894, 1.089] 0.771
[0.554, 1.074] 0.879
[0.728, 1.060]
25.01
0.992
[0.887, 1.111] 0.622**
[0.437, 0.885] 0.857
[0.689, 1.065]
Note. Any visit to other medical specialist was analyzed only among those with the corresponding chronic condition
(e.g., any visit to endocrinologists was analyzed among those with diabetes).
CI: Confidence intervals; COPD: Chronic Obstructive Pulmonary Disease; OR: Odds ratios.
***p<.001 **.001<p<.01 *p<.05
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Appendix 2.6 Adjusted Estimates from Negative Binomial
Regression with Generalized Estimating Equation on Number of
PCP Visits with Inverse Probability Treatment Weights among
Elderly with Diffuse Large B-Cell Lymphoma. Surveillance
Epidemiology and End Results Program (SEER) Medicare
2003-2011.
Number of PCP Visits
β
SE
Time
Baseline, t1
Ref.
Pre-diagnosis,t2
0.133***
0.016
Treatment,t3
0.491***
0.028
Post-treatment,t4
0.027
0.022
Short followup,t5
-0.121***
0.02
Long followup,t6
-0.108***
0.022
Age groups
66-69
Ref.
70-74
0.041
0.024
74-79
0.046
0.025
>=80
0.082***
0.025
Sex
Female
0.059***
0.017
Male
Ref.
Race
Whites
Ref.
African American
-0.065
0.04
Hispanics
0.070
0.055
Others
0.065
0.033
Marital status
Single
Ref.
Married
-0.049
0.037
Separated/Divorced/
Widowed
-0.036
0.039
Region
Northeast
Ref.
South
0.089**
0.032
North-Central
0.139***
0.033
West
0.100***
0.027
Rural/Urban
Metro
Ref.
Urban
0.044
0.027
Rural
0.005
0.056
DLBCL stage
Stage I
Ref.
Stage II
-0.020
0.023
Stage III
-0.007
0.025
Stage IV
0.030
0.021
Radiotherapy
Yes
0.085***
0.023
No
Ref.
Chemotherapy
Yes
-0.025
0.024
No
Ref.
Immunotherapy
Yes
0.099***
0.028
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Appendix 2.6 Adjusted Estimates from Negative Binomial
Regression with Generalized Estimating Equation on Number of
PCP Visits with Inverse Probability Treatment Weights among
Elderly with Diffuse Large B-Cell Lymphoma. Surveillance
Epidemiology and End Results Program (SEER) Medicare
2003-2011.
Number of PCP Visits
β
SE
No
Ref.
Stem cell transplant
Yes
-0.060***
0.017
No
Ref.
Arthritis
Yes
0.171***
0.016
No
Ref.
Diabetes
Yes
0.209***
0.016
No
Ref.
Any heart condition
Yes
0.295***
0.016
No
Ref.
Depression/Anxiety
Yes
0.324***
0.021
No
Ref.
Asthma/COPD
Yes
0.170***
0.017
No
Ref.
County% blacks
1.14
Ref.
4.21
-0.059*
0.025
9.46
-0.007
0.03
28.38
-0.093**
0.032
County% hospitals
0.56
Ref.
0.96
0.024
0.025
1.30
-0.001
0.024
3.48
-0.038
0.028
County% without health insurance
12.89
Ref.
17.21
0.015
0.025
22.07
-0.048
0.03
28.24
-0.074*
0.033
County average travel time
19.50
Ref.
24.09
-0.037
0.023
27.42
-0.010
0.025
31.06
-0.050
0.027
County% less than high school
education
8.27
11.99
0.039
0.024
15.75
0.082**
0.028
24.52
0.118***
0.031
Note. Based on 5,455 Medicare beneficiaries with Diffuse Large B-Cell Lymphoma (DLBCL) who had at least one
PCP visit during t1 to t6. Adjusted beta coefficients and standard errors are from Generalized Estimating Equation
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with negative binomial distribution and unstructured correlation matrix. COPD: Chronic Obstructive Pulmonary
Disease; PCP: Primary Care Physician.
***p<.001 **.001<p<.01 *p<.05
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Chapter 3: Receipt of Mammography and Bone Density Testing by Women with Diffuse
Large B-Cell Lymphoma.
3.1 Abstract
Background. Women with Diffuse Large B-Cell Lymphoma (DLBCL) are at a higher
risk of breast cancer and osteoporosis than the general population. The receipt of mammography
and bone mineral density testing (BDT) by women with DLBCL is unknown. Objective. We
utilized a social-ecological model (SEM) with Surveillance, Epidemiology, and End Results
(SEER)-Medicare linked dataset to analyze the receipt of mammography among female DLBCL
patients (n=1,137) aged 66-74 years and BDT among those aged >66 years (n=3,029) compared
to female non-cancer patients (n=6,376 & 13,366, respectively). Methods. We used multivariable
logistic regressions with Inverse Probability Treatment Weights to control for observed selection
bias. Results. There was no significant difference in mammography between women with
DLBCL (59.8%) and no cancer (60.2%); both of which were well below the Healthy People
2020 target (81.1%; both p < .0001). Female DLBCL patients had slightly lower rate of BDT
(18.5%) than non-cancer patients (19.6%; p > .05). After adjusting for PCP visits, DLBCL
patients were less likely to have mammography (AOR [95%CI]: 0.82 [0.71, 0.94]) and BDT
(0.80 [0.71, 0.90]) than non-cancer patients. Further, those with more primary care physician
visits were more likely to have mammography (1.62 [1.48, 1.77]) and BDT (1.60 [1.50, 1.71]).
Radiotherapy and stem cell transplant were not associated with mammography and BDT,
respectively (both p >.05). Conclusions. Prioritization of cancer and chronic care may be causing
sub-optimal mammography and BDT among female DLBCL patients. Providers should increase
the recommendations for mammography in those receiving radiotherapy and BDT in stem cell
transplant patients, to reduce the morbidity and mortality from breast cancer and fractures in
women with DLBCL.
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3.2 Introduction
Non-Hodgkin’s Lymphoma (NHL) is the most common hematologic cancer in the United
States, with about 72,580 new cases diagnosed in 2016.1 Diffuse Large B-Cell Lymphoma
(DLBCL) is the most common subtype of NHL and commonly occurs in adults above 64 years
of age.2 Advances in the treatment of DLBCL such as immunotherapy with Rituximab3 and
hematopoietic stem cell transplantation4 have led to a marked improvement in the five-year
survival rate to approximately 60.5%.5 However, DLBCL patients are at a higher risk of
secondary cancers and adverse treatment effects than general population.6,7 Of particular concern
are the risks of breast cancer and loss of bone mineral density among women with DLBCL.4,6
3.2.1 Risk of Breast Cancer
Breast cancer is the most common cancer among women, with 246,660 new cases
expected to be diagnosed in 2016.8 Older female DLBCL patients who received radiotherapy are
at a threefold risk of breast cancer than general population.6,9,10 Female breast cancer patients
with a history of lymphoma had significantly lower five-year disease free survival (54%) and
overall survival (87%) as compared to breast cancer patients with no history of lymphoma (91%
and 98%, respectively).11 Breast cancer screening with mammography can lead to early
treatment due to good sensitivity (68%) and high specificity (93%) for detecting breast cancer in
lymphoma patients.12-14
Increasing the rate of mammography screenings is essential to meet the Healthy People
2020 target of 81.1% for women aged 50-74 years.15 Since 2009, the US Preventive Services
Task Force (USPSTF) recommends biennial mammography screening for women between 50-74
years of age.16 Consistent with the USPSTF guidelines, the American Cancer Society also
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recommends mammograms every 2 years for women aged 55 and older.17 It is critical to
examine the receipt of mammography among DLBCL patients as mammography use can be
negatively affected by the competing demands of acute DLBCL treatment, which the provider
may deem more necessary for patient’s survival.18-20
3.2.2 Risk of Bone Density Loss
Another well-known adverse consequence of DLBCL treatment is the loss of bone
density in women, which can lead to negative sequelae such as osteoporosis and fractures.4,21
Bone density loss is high in elderly post-menopausal women,22 which can be aggravated by
chemotherapy, corticosteroids, and hematopoietic cell transplantation in women with DLBCL.2325

For example, female lymphoma patients who received stem cell transplant had eightfold odds

of reporting osteoporosis than siblings without cancer.24 NHL patients with chemotherapy had
higher rates of fractures (31%) and osteoporosis (10%) as compared to NHL patients who did not
receive chemotherapy (19% and 8%, respectively). The USPSTF recommends bone mineral
density testing (BDT) for osteoporosis in women aged ≥65 years without previous known
fractures or secondary causes of osteoporosis.26 BDT by dual photon densitometry at one year is
recommended among stem cell transplant recipients due to their elevated risk of having bone
density loss.27
Older Medicare beneficiaries have been found to have low rates of BDT in a previous
study.28 Some reasons for underuse of BDT include the uncertainty of site and frequency of
testing, lack of a cut-off value for fracture risk, and limited predictive value of BDT for
fractures.29 Further, there are several other risk factors for fractures which are independent of
bone mineral density such as history of fracture, maternal history of fracture, age, and low serum
levels of estradiol.29 However, BDT is currently the most effective measure for predicting the
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risk of fractures in post-menopausal women30-3233 and should be provided to female DLBCL
patients. Increasing the rates of BDT is crucial to achieve the Healthy People 2020 target of
reducing osteoporosis cases and hospitalizations due to fractures.34
3.2.3 Predictors of Screenings
Cancer patients have been found to be more likely to have preventive screenings than
non-cancer patients. For example, breast cancer patients were more likely to receive
mammography (74.0%) and BDT (8.3%) than matched non-cancer controls (41.0% and 6.8%,
respectively).35 Similarly, colorectal cancer patients were more likely to receive a mammogram
(49.8%) than matched non-cancer patients (47.4%).36 Primary Care Physicians (PCPs) play an
important role in providing preventive screenings to women with cancer,35,37,38 and
recommendation by PCP is the one of the best predictors of cancer screening adherence.39,40
Breast cancer patients with more visits to PCP were twice as likely to receive mammography37
and colorectal patients with more PCP visits were twice as likely to receive BDT.41 We could not
identify any study examining the use of mammography and BDT among women with DLBCL;
research investigating mammography and BDT in this population is needed, as DLBCL is a
more aggressive cancer and is treated with an intense therapeutic regimen, which may increase
the risk for second primary cancers.42 DLBCL treatment increases the risk of breast cancer and
loss of bone density in women, and it is necessary to analyze the factors that can affect
mammography screening and BDT in these patients to improve their quality and quantity of life.
3.3 Theoretical Framework
We utilized the Social Ecological Model (SEM) to examine the factors that can affect the
receipt of mammography and BDT. The SEM is an overarching theoretical framework to
examine the association of diverse personal and surrounding socio-physical factors with a health
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behavior.43,44 These factors consist of: 1) intra-personal factors - patient’s demographic
characteristics, other chronic conditions, and treatments received for DLBCL; 2) inter-personal
factors – patients’ social network of friends, family, or colleagues; (c) healthcare system factors
– availability of hospitals and physicians; and (d) community factors - characteristics of the
surrounding geographical area including SEER region, urban/rural region, area poverty, and area
education.44-46 Previous studies have used the SEM to examine the geographic variations in
mammography and colorectal screenings.45,47,48 We utilized this framework to examine the
association of multiple individual and contextual factors with the receipt of mammography and
BDT in women with DLBCL as compared to women without any cancer.
3.4 Methods
3.4.1 Study Design
We used a retrospective cohort study design with 12 month baseline and 24 month
follow-up periods. We identified the baseline and follow-up periods using the DLBCL diagnosis
date as the index date for DLBCL patients. For the non-cancer patients, we derived the baseline
and follow-up periods by using a random service date from inpatient or outpatient Medicare
claims.
3.4.2 Data Sources
We utilized the following data sources for this study: 1) Surveillance, Epidemiology and
End Results Program (SEER) cancer registry data; 2) 5% sample of Medicare patients without
any cancer; 3) Medicare claims of patients from SEER and non-cancer patients; and 4) the Area
Health Resource File (AHRF). SEER is an epidemiologic cancer surveillance system including
data from 20 cancer registries (Alaska Native Tumor Registry, Arizona Indians, Cherokee
Nation-Oklahoma, Connecticut, Detroit, Atlanta-Georgia, Greater Georgia, Rural Georgia, San
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Francisco-Oakland, San Jose-Monterey, Greater California, Hawaii, Iowa, Kentucky, Los
Angeles, Louisiana, New Jersey, New Mexico, Seattle-Puget Sound, and Utah).49 These cancer
registries collect information for patients with newly diagnosed cancers such as patient’s
demographic characteristics, site of cancer diagnosis, date of cancer diagnosis, and cancer stage
or grade (e.g., DLBCL stage). Medicare claims of beneficiaries who resided in SEER areas can
be linked to the SEER registries to collect detailed information on medical treatment, chronic
conditions, healthcare utilization, and costs.
The AHRF is a publicly available data provided by the Department of Health and Human
Services.50 We used the AHRF file to obtain information on the availability of health
professionals, healthcare facilities, and socioeconomic and environmental characteristics of each
county. We used the state and county Federal Information Processing Standard (FIPS) codes to
link the SEER-Medicare dataset with AHRF files.
3.4.3 Study Sample
For the outcome of BDT, we included 3,029 female Medicare beneficiaries with age >66
years with a primary diagnosis of DLBCL (International Classification of Diseases for Oncology
- Third Revision (ICD-O-3)/World Health Organization 2008 codes: 13, 14, 15, 16) during 20032011 (Appendix 3.1). For mammography screening, we included 1,137 female beneficiaries with
a primary diagnosis of DLBCL who were between 66-74 years of age (Appendix 3.1). We only
included patients who had one primary DLBCL cancer diagnosis (except basal cell carcinoma)
and who were not diagnosed with cancer from autopsy.
We selected the non-cancer patients from a random 5% sample of Medicare beneficiaries
who resided in SEER areas during 2003-2011 and were not diagnosed with any cancer, except
basal cell carcinoma. From this non-cancer dataset, we selected a 10% random sample of female
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Medicare beneficiaries as the comparison group. We included 11,956 female Medicare
beneficiaries > 66 years of age for BDT and 5,686 female beneficiaries between 66-74 years of
age for mammography screening as the non-cancer comparison group (Appendix 3.2).
We applied the following exclusion criteria to both DLBCL and non-cancer patients: 1)
less than 66 years of age; 2) having End Stage Renal Disease (ESRD); 3) not alive during the
baseline or follow-up periods; 4) enrolled in managed care plans; 5) not continuously enrolled in
Medicare parts A and B during the baseline and follow-up periods; 6) not having any PCP visit
during the baseline and follow-up periods; and 7) missing values for age, sex, race, region, or
ESRD.
3.4.4 Measures
Dependent variables. We analyzed two dependent variables in this study: the receipt of
mammography screening and the receipt of BDT. Before 2009, mammography screening was
recommended every 1-2 years for women aged 40 and older.51 In 2009, the USPSTF revised the
recommended screening mammography interval to every two years. To examine if the rates of
mammography are consistent with the current USPSTF and American Cancer Society guidelines,
we used the time interval of two years for mammography screening in our study. For
osteoporosis screening, although the USPSTF has not recommended an optimal interval for
repeated screening, a minimum of two years period has been suggested to reliably detect a
change in bone mineral density.31,52 Hence, we measured the receipt of osteoporosis screening
during the two year follow-up period. Further, we adjusted for the year of index date as one of
the independent variable. We used the diagnosis and procedure codes in inpatient and outpatient
Medicare claims files to measure these variables. We excluded diagnostic mammography
screening from the analysis and only included the codes for screening mammography. We
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included BDT with dual energy X-Ray absorptiometry, photon absorptiometry, or Computed
Tomography scan in this study.29
Key Independent Variable – Cancer Status. The key independent variable for this study was
the presence of DLBCL compared with no cancer. The diagnosis of DLBCL belonged to the
domain of intra-personal factors from the SEM.
SEM Independent Variables
The intra-personal factors of radiotherapy, chemo-immunotherapy and stem cell
transplant for DLBCL patients were measured during one year after the DLBCL diagnosis. All
other intra-personal, inter-personal, healthcare system, and community factors were measured
during the one year baseline period before the index date.
Intra-personal factors. 1) Average monthly PCP visits before first mammography or
first BDT: PCP specialties included general practice, family practice, internal medicine, geriatric
medicine, nurse practitioner, physician assistant, or obstetrics-gynecology.35 ObstetricsGynecologists serve as PCPs for many women53-55 and have been included as a PCP specialty in
previous studies.56 Among those who did not receive mammography or BDT, we calculated the
average monthly visits to PCP during the follow-up period of 24 months. We identified PCP
specialty by using the Health Care Financing Administration (HCFA) specialty codes35,57,58 ; 2)
age at index date (66-69 or 70-74 yrs.); 3) race (Non-Hispanic White, Non-Hispanic African
American, Hispanic, or others); 4) rurality: We used urban/rural recode to classify region into
metro (counties with <250,000 to one million population), urban (counties with 2,500 to >20,000
population), and rural (counties with less than 2,500 population)49; 5) geographic region
(Northeast, South, North-Central, or West); 6) arthritis (osteoarthritis or rheumatoid arthritis); 7)
any heart condition (cardiac arrhythmia, congestive heart failure, or coronary artery disease); 8)
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diabetes; 9) depression or anxiety; and 10) Asthma or Chronic Obstructive Pulmonary Disease
(COPD). The intra-personal factors specific to DLBCL patients included: 1) Ann Arbor stage of
DLBCL (stage I, II, III or IV); 2) radiotherapy; 3) chemo-immunotherapy; and 4) stem cell
transplant.
Inter-personal factors. Inter-personal factors included county-level 1) percentage of
Blacks; 2) percentage of Hispanics; and 3) percentage of non-English speaking individuals above
18 years of age.
Healthcare system factors. Healthcare system factors included county level: 1) average
number of hospitals per 10,000 individuals above 65 years of age; 2) PCP shortage area (whole
county, part of county, or no shortage); and 3) average number of Federal Qualified Health
Centers (FQHC) per 10,000 individuals above 65 years of age.
Community factors. Community factors included county level: 1) percentage of
individuals without health insurance; 2) average travel time to work; and 3) percentage of
individuals with below high school education.
In addition to the SEM factors, we included year of index date as a covariate in all the
analyses. A small number of individuals received BDT during 2003 to 2006. Hence, we
combined the index years 2003-2006 into a single level and used the following categories for the
outcome of BDT: 2003-2006, 2007, 2008, 2009, 2010, and 2011. For mammography, the year of
index date was categorized into two groups of: before 2009 and after 2009 to examine the impact
of change in USPSTF guidelines in 2009.51
3.4.5 Statistical Analyses
We analyzed the differences in intra-personal, inter-personal, healthcare, and community
factors between the DLBCL and the non-cancer patients by using chi-square tests. We used
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logistic regressions to analyze the relationship of DLBCL diagnosis, PCP visits, and other intrapersonal, inter-personal, healthcare system, and community factors with the receipt of
mammography screening and BDT. From our preliminary analysis, we found that there were
significant differences in some characteristics between the DLBCL and non-cancer patients. In
order to decrease this observed selection bias, we estimated Inverse Probability Treatment
Weights (IPTW) by conducting logistic regression on DLBCL compared with no cancer with the
independent variables of age, race/ethnicity, index year, geographic region, diabetes, any heart
condition, asthma/COPD, arthritis, and depression/anxiety. We used these IPTWs as weights in
all the unadjusted and adjusted analyses. All analyses were conducted using SAS version 9.4.59
3.5 Results
3.5.1 Characteristics of Female DLBCL and Non-Cancer Patients
Table 3.1 summarizes the selected characteristics of female DLBCL and non-cancer
patients above 65 years of age, before and after adjusting with IPTW. Before adjusting with
IPTW, a higher percentage of Whites compared to Blacks, those aged >70 years compared to 6669 years, living in Northeast compared to South, those with arthritis compared to those without
arthritis, those with any heart condition compared to those without any heart condition, and those
with asthma/COPD compared to those without asthma/COPD had DLBCL.
3.5.2 DLBCL and Mammography
Table 3.2 summarizes the characteristics of female Medicare beneficiaries by the receipt
of mammography screening. From chi-square tests, rates of mammography between DLBCL
(59.8%) and non-cancer patients (60.2%) did not differ. Further, the mammography rates for
both DLBCL and non-cancer female patients were significantly lower than the Healthy People
2020 target of 81.1% (both p < .0001). From logistic regression model 1, without adjusting for
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PCP visits, screening mammography between DLBCL and non-cancer patients did not differ
(adjusted odds ratio [95%CI]: 0.98 [0.86, 1.13]). However, after adjusting for monthly PCP visits
in model 2, DLBCL patients were less likely than non-cancer patients to receive mammography
screening (0.82 [0.71, 0.94]).
3.5.3 PCP Visits and Mammography
From model 2, female beneficiaries with more monthly visits to PCPs were more likely
to receive mammography screening (1.62 [1.48, 1.77]) (Table 3.2). Further, those aged 70-74
years compared to 66-69 years, those with other races compared to Whites, those with
asthma/COPD compared to those without asthma/COPD, those with depression/anxiety
compared to those without depression/anxiety, those with diabetes compared to those without
diabetes, tobacco users compared to non-tobacco users, and those living in counties with more
African Americans compared to counties with less African Americans were less likely to have
mammography. Also, those living in metro compared to rural regions and those with arthritis
compared to those without arthritis were more likely to have mammography.
3.5.4 DLBCL and Bone Density Testing
Table 3.3 summarizes the characteristics of female Medicare beneficiaries by the receipt
of BDT. From chi-square test, the receipt of BDT between DLBCL (18.5%) and non-cancer
patients (19.6%) did not differ (p = .173). From logistic regression model 3, without adjusting for
PCP visits, BDT between DLBCL and non-cancer patients did not differ (0.94 [0.84, 1.05]).
After adjusting for monthly PCP visits in model 4, DLBCL patients were less likely than noncancer patients to receive BDT (0.80 [0.71, 0.90]).
3.5.5 PCP Visits and Bone Density Testing
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From model 4, female beneficiaries with more monthly visits to PCPs were more likely
to receive BDT (1.60 [1.50, 1.71]) (Table 3.3). Further, those aged above 70 years compared to
66-69 years, African Americans compared to Whites, those living in urban compared to rural
regions, those with any heart condition compared to those without any heart condition, those
with depression/anxiety compared to those without depression/anxiety, and those with diabetes
compared to those without diabetes were less likely to have BDT. Also, those living in South
compared to North-East, those with index years > 2007 compared to 2003-2006, those with
arthritis compared to those without arthritis, and those living in counties with more Hispanics
compared to counties with less Hispanics were more likely to have BDT.
3.5.6 Mammography and BDT among DLBCL Patients
Among female DLBCL patients, more monthly PCP visits was associated with higher
odds of receiving mammography screening (1.34 [1.17, 1.54]) and BDT (1.47 [1.32, 1.63]).
Further, among DLBCL patients, those with other races compared to Whites (0.45 [0.26, 0.79])
and those living in counties with more travel time (0.44 [0.29, 0.67]) compared to less travel time
were less likely to have mammography. Also, married women compared to unmarried women
(2.10 [1.32, 3.36]) were more likely to receive mammography screening. Radiotherapy was not
significantly associated with mammography (1.04 [0.77, 1.39]).
With respect to BDT, more visits to PCPs was associated with higher odds of BDT
among DLBCL patients (1.46 [1.31, 1.62]). Further, among DLBCL patients, African Americans
compared to Whites (0.38 [0.19, 0.75]) were less likely and those living in counties with more
Hispanics compared to counties with less Hispanics (2.67 [1.69, 4.23]) were more likely to
receive BDT. With respect to DLBCL treatments, patients receiving chemo-immunotherapy
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were more likely to receive BDT (2.27 [1.42, 3.62]). Stem cell transplant was not significantly
associated with BDT (1.15 [0.94, 1.41]).
3.6 Discussion
We conducted this study to examine the receipt of mammography and BDT among
female patients with DLBCL who are at a higher risk of breast cancer and loss of bone density
than general population. We used a social-ecological model to analyze the relationship of diverse
personal and environmental factors which can influence the receipt of mammography and BDT
among female Medicare beneficiaries with DLBCL compared to those without cancer.
The rates of mammography need to be increased for both DLBCL and non-cancer female
patients to meet the Healthy People 2020 target.15 Although DLBCL patients are at a higher risk
of breast cancer and osteoporosis, without adjusting for PCP visits, there was no significant
difference in mammography and BDT between DLBCL patients and non-cancer patients. These
results are inconsistent with previous studies in breast and colorectal cancer patients, which
found that cancer patients receive more mammograms and BDT than non-cancer patients.35,36,60
One explanation is that DLBCL is a more aggressive form of cancer and requires more intensive
treatment than breast and colorectal cancer. Further, we found that DLBCL patients with chronic
conditions such as diabetes and depression/anxiety were less likely to receive mammography
screening and BDT. The providers may be prioritizing the acute DLBCL treatment and
management of other comorbid conditions than preventive screenings in DLBCL patients.
After adjusting for PCP visits, DLBCL patients were less likely than non-cancer patients
to receive mammography and BDT. Further, more PCP visits was associated with higher
mammography and BDT, which indicates the importance of visiting PCPs for receiving
preventive screenings.39 Providers should increase the recommendations for mammography and
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BDT in DLBCL patients, and perhaps DLBCL will benefit the most from seeing their PCP,
particularly in terms of preventive screenings. DLBCL patients have a favorable prognosis and
most patients have long survival period after treatment. These patients can benefit by receiving
preventive screenings to further improve their quality of life. Further, oncologists should
encourage their patients to visit their PCPs frequently to increase their mammography screening
and BDT. Although arthritis patients have been found to have lower risk of breast cancer,61-64 we
found that those with arthritis were more likely to receive mammography. Future studies need to
examine the reason for higher mammography use among arthritis patients. We found that the
rates of BDT increased four times after 2006. Even though the rates of BDT remain lower than
nationally recommended levels, it shows the increase in availability and awareness of BDT in
recent years among elderly Medicare beneficiaries.
The risk of breast cancer and osteoporosis varies with the treatment received among
DLBCL patients. Female DLBCL patients receiving radiotherapy are at a higher risk of breast
cancer6 and those receiving stem cell transplant are at a higher risk of osteoporosis.24 However,
we did not find a significant relationship between radiotherapy and mammography screening.
Further, the stem cell transplant was not associated with BDT in female DLBCL patients. These
results indicate the need for higher mammography screening among female DLBCL patients
receiving radiotherapy and higher BDT among stem cell transplant recipients.
The rate of mammography was lower among women aged 70-74 years as compared to
66-69 years, and BDT was lower among those aged above 70 years as compared to 66-69 years,
which is consistent with previous studies.36,65 It may be due to belief that preventive services
may provide little gain in life expectancy for those with higher age. However, we adjusted for
patients’ other chronic conditions to control for their physical and mental comorbidities. Also,
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continuing mammography screening in women between 70-74 years of age has been found to be
cost-effective and can increase survival.65-67 Similarly, BDT can prevent fractures among elderly
women.68-70 Hence, mammography should be not be stopped for women with 70-74 years of age
and BDT should be continued among women above 70 years of age as recommended by the
USPSTF guidelines.
Our study has some limitations. We used the HCFA specialty codes given in the SEERMedicare dataset to identify the PCP specialties in this study. The HCFA codes have been used
in previous studies,20,35,71 but these codes may not capture all the visits to different provider
specialties.72 Our study results are generalizable to female beneficiaries enrolled in fee-forservice Medicare. A strength of our study is that we used a large nationally representative data of
patients with newly diagnosed cancer. We examined a comprehensive set of personal and
contextual factors in our multivariate models. Further, we used a robust study design with IPTW
adjusted analyses to reduce observed selection bias between women with DLBCL and no cancer.
3.7 Conclusions
There was no significant difference in mammography and BDT between female DLBCL
patients and women with no cancer. After adjusting for PCP visits, women DLBCL patients were
less likely than non-cancer patients to receive mammography and BDT. Those with more PCP
visits were more likely to have mammography and BDT. Further, those between 70-75 years of
age were less likely to receive mammography and those aged above 70 years were less likely to
receive BDT than women between 66-69 years of age. Female DLBCL survivors are at a higher
risk of breast cancer and osteoporosis and need to receive more preventive screenings.
Implications for Practice and/or Policy
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Our study results suggest that providers should increase their recommendations for breast
cancer screening and BDT in women with DLBCL. Rates of mammograms need to be increased
for women treated with radiotherapy while BDT should be increased among women who
received stem cell transplant. Current guidelines recommend breast cancer screening for women
with Hodgkin’s lymphoma and BDT for stem cell transplant recipients. Similar clinical
guidelines are required for preventive screenings for women with Non-Hodgkin’s Lymphoma,
which is four times more common than Hodgkin’s Lymphoma.
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Table 3.1 Description of Selected Characteristics of Female Medicare Beneficiaries above 65 Years
of Age with Diffuse Large B-Cell Lymphoma (DLBCL) and No Cancer before and after Inverse
Probability Treatment Weights. Surveillance Epidemiology and End Results Program (SEER) Medicare 2003-2011.
DLBCL
No Cancer
DLBCL
No Cancer
col%
n
col%
sig IPTW col% IPTW col%
n
Total
3,029 100.0 11,956 100.0
Age
***
66-69 yrs.
535
17.7
2,914
24.4
23.0
23.0
>70 yrs.
2,494 82.3
9,042
75.6
77.0
77.0
Race
***
White
2,645 87.3
9,877
82.6
83.4
83.6
African American
121
4.0
940
7.9
7.3
7.1
Hispanic
78
2.6
272
2.3
2.3
2.3
Others
185
6.1
867
7.3
7.0
7.0
Region
***
Northeast
667
22.0
2,371
19.8
20.5
20.3
South
705
23.3
3,207
26.8
25.8
26.1
North-central
401
13.2
1,448
12.1
12.3
12.3
West
1,256 41.5
4,930
41.2
41.4
41.3
Rural Urban
Metro
2,514 83.0
9,926
83.0
83.1
83.1
Urban
455
15.0
1,791
15.0
15.0
14.9
Rural
60
2.0
239
2.0
2.0
2.0
Index year
**
2003
341
11.3
1,409
11.8
11.7
11.7
2004
349
11.5
1,325
11.1
11.5
11.2
2005
334
11.0
1,277
10.7
10.9
10.8
2006
326
10.8
1,158
9.7
10.1
9.9
2007
336
11.1
1,207
10.1
10.2
10.3
2008
357
11.8
1,245
10.4
10.6
10.7
2009
331
10.9
1,320
11.0
11.0
11.0
2010
323
10.7
1,403
11.7
11.4
11.5
2011
332
11.0
1,612
13.5
12.5
13.0
Arthritis

***
Yes

1,125

37.1

3,895

32.6

No

1,904

62.9

8,061

67.4

Any Heart Condition
Yes
No
Asthma/COPD
Yes
No
Depression/Anxiety
Yes
No
Diabetes
Yes

33.3

33.5

66.7

66.5

***
1,227

40.5

4,422

37.0

38.2

37.7

1,802

59.5

7,534

63.0

61.8

62.3

643

21.2

2,202

18.4

19.2

19.0

2,386

78.8

9,754

81.6

80.8

81.0

417
2,612

13.8
86.2

1,741
10,215

14.6
85.4

14.8
85.2

14.4
85.6

892

29.4

3,443

28.8

29.7

28.8

***

***

***

92

No
2,137 70.6
8,513
71.2
70.3
71.2
Note. Based on 3,029 female Medicare beneficiaries with Diffuse Large B-Cell Lymphoma and a random sample of
11,956 female beneficiaries without any cancer who resided in SEER areas. Weighted percentages were derived
with using inverse probability treatment weights. COPD: Chronic Obstructive Pulmonary Disease; Sig. significance
level.
***p<.001 **.001< p<.01
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Table 3.2 Unadjusted Differences and Adjusted Odds Ratios for Screening Mammography by Selected Characteristics of
Female Medicare Beneficiaries between 66-74 years of age after Inverse Probability Treatment Weights. Surveillance
Epidemiology and End Results Program (SEER) - Medicare 2003-2011.
Screening Mammography
Yes
n
Total

No

IPTW row%
2,720
4,103

Model 1
Sig.

AOR

95% CI

0.98
Ref.

[0.86, 1.13]

Model 2
Sig.

AOR

95% CI

Sig.

0.82
Ref.

[0.71, 0.94]

**

1.62

[1.48, 1.77]

***

0.80
Ref.

[0.72, 0.89]

***

0.97
1.10
0.57
Ref.

[0.79, 1.18]
[0.76, 1.58]
[0.47, 0.70]

***

DLBCL
Yes
No Cancer
Mean Monthly PCP Visits

1,137
5,686

59.8
60.2

40.2
39.8

0.43

0.80

0.54

Age

***

NA

***
70-74 yrs.
66-69 yrs.

3,374
3,449

57.5
62.8

42.5
37.2

0.80
Ref.

[0.72, 0.89]

African American
Hispanic
Others
White

541
149
512
5,621

58.7
60.3
49.4
61.3

41.3
39.7
50.6
38.7

0.97
1.07
0.59
Ref.

[0.79, 1.18]
[0.75, 1.53]
[0.48, 0.72]

South
North-central
West

1,903
803
2,893

59.5
59.7
60.5

40.5
40.3
39.5

1.17
0.97

[0.98, 1.41]
[0.80, 1.19]

1.12
0.92

[0.93, 1.35]
[0.75, 1.12]

[0.95, 1.34]

60.4

39.6

1.10
Ref.

[0.92, 1.31]

1,224

1.13
Ref.

Northeast
Metro
Urban

5,612
1,080

60.5
59.2

39.5
40.8

[1.09, 2.40]
[0.96, 2.09]

*

*

131

51.9

48.1

1.57
1.35
Ref.

[1.05, 2.35]
[0.91, 2.01]

Rural

1.62
1.42
Ref.

Yes

1,964

61.4

38.6

**

*

59.6

40.4

1.15
Ref.

[1.02, 1.29]

4,859

1.19
Ref.

[1.06, 1.34]

No

1,974
4,849

58.0
61.0

42.0
39.0

1.00
Ref.

[0.88, 1.12]

0.92
Ref.

[0.82, 1.04]

0.82
Ref.

[0.71, 0.93]

**

0.78
Ref.

[0.68, 0.90]

***

0.78
Ref.

[0.67, 0.90]

***

0.71
Ref.

[0.61, 0.82]

***

0.86
Ref.

[0.77, 0.97]

*

0.80
Ref.

[0.71, 0.90]

***

0.48
Ref.

[0.36, 0.65]

***

0.46
Ref.

[0.34, 0.62]

***

Race

***

***

***

Region

Rurality

Arthritis

Any Heart Condition
Yes
No
Asthma/COPD
Yes
No
Depression/Anxiety
Yes
No
Diabetes
Yes
No
Tobacco Use
Yes
No
Index Year

*

***
1,236
5,587

54.5
61.4

45.5
38.6

1,000
5,823

54.9
61.0

45.1
39.0

2,012
4,811

56.5
61.7

43.5
38.3

214
6,609

41.3
60.7

58.7
39.3

***

***

***
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Table 3.2 Unadjusted Differences and Adjusted Odds Ratios for Screening Mammography by Selected Characteristics of
Female Medicare Beneficiaries between 66-74 years of age after Inverse Probability Treatment Weights. Surveillance
Epidemiology and End Results Program (SEER) - Medicare 2003-2011.
After 2009
1,990
59.7
40.3
0.97
[0.86, 1.08]
0.96
[0.86, 1.08]
Before 2009
4,833
Ref.
Ref.
60.3
39.7
County% Blacks
**
4.45
1,686
60.8
39.2
0.87
[0.74, 1.02]
0.85
[0.72, 1.00]
10.09
1,701
57.2
42.8
0.79
[0.66, 0.95]
*
0.78
[0.65, 0.93]
31.12
1,710
58.9
41.1
0.80
[0.65, 0.97]
*
0.79
[0.64, 0.97]
1.22
1,726
63.7
36.3
Ref.
Ref.
County% Less than High
***
School Education
12.48
1,697
63.3
36.7
0.98
[0.84, 1.14]
0.98
[0.84, 1.15]
16.71
1,731
59.0
41.0
0.80
[0.69, 0.94]
**
0.82
[0.70, 0.96]
25.37
1,698
54.6
45.4
0.68
[0.57, 0.82] *** 0.67
[0.56, 0.80]
8.48
1,697
63.7
36.3
Ref.
Ref.
Note. Based on 1,137 female Medicare beneficiaries with Diffuse Large B-Cell Lymphoma and a random sample of 5,686
female beneficiaries without any cancer between 66-74 years of age who resided in SEER areas. Weighted percentages
were derived with using inverse probability treatment weights. COPD: Chronic Obstructive Pulmonary Disease; PCP:
Primary care physician; Sig. significance level.
***p<.001 **.001< p<.01 *.01< p<.05
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**
*

*
***

Table 3.3 Unadjusted Differences and Adjusted Odds Ratios for Bone Density Testing by Selected Characteristics of Female
Medicare Beneficiaries above 65 years of Age after Inverse Probability Treatment Weights. Surveillance Epidemiology and End
Results Program (SEER) - Medicare 2003-2011.
Bone Density Testing
Yes
n
Total

No

IPTW row%

14,985

19.5

80.5

3,029
11,956

18.5
19.6

81.5
80.4

0.46

0.95

0.60

Sig.

AOR

Model 3
95% CI

Sig.

AOR

Model 4
95% CI

Sig.

DLBCL
Yes
No Cancer
Mean Monthly PCP Visits
Age

0.94
Ref.
***

[0.84, 1.06]

0.80
Ref.

[0.71, 0.90]

***

NA

1.60

[1.50, 1.71]

***

0.61

[0.55, 0.68]

***

***

***
>70 yrs.

11,536

17.3

82.7

0.64

66-69 yrs.

3,449

26.2

73.8

Ref.

Race

[0.58, 0.71]

***

Ref.

***
African American

1,061

12.0

88.0

0.51

[0.41, 0.62]

0.51

[0.41, 0.63]

350

18.6

81.4

0.76

[0.56, 1.03]

0.81

[0.60, 1.10]

Others

1,052

19.7

80.3

0.90

[0.75, 1.07]

0.89

[0.74, 1.06]

White

12,522

20.0

80.0

Ref.

South

3,912

18.4

81.6

1.39

[1.17, 1.66]

***

1.38

[1.16, 1.66]

***

North-central

1,849

18.4

81.6

1.34

[1.10, 1.63]

**

1.27

[1.03, 1.55]

*

West

6,186

20.5

79.5

0.94

[0.82, 1.08]

0.94

[0.82, 1.08]

Northeast

3,038

18.9

81.1

Ref.

Hispanic

***

Ref.

Region

Rural / Urban

Ref.

***
Metro

12,440

20.0

80.0

0.86

[0.61, 1.19]

Urban

2,246

16.0

84.0

0.68

[0.49, 0.96]

Rural

299

19.5

80.5

Ref.

Yes

5,020

21.2

78.8

1.29

No

9,965

18.5

81.5

Ref.

Yes

5,649

18.6

81.4

0.98

No

9,336

19.9

80.1

Ref.

Yes

2,845

19.0

81.0

0.99

No

12,140

19.5

80.5

Ref.

Yes

2,158

19.2

80.8

0.85

No

12,827

19.4

80.6

Ref.

Arthritis

*

0.80

[0.57, 1.12]

0.65

[0.46, 0.92]

*

[1.10, 1.34]

***

[0.81, 0.99]

*

Ref.

***
[1.17, 1.42]

***

1.22
Ref.

Any Heart Condition
[0.89, 1.08]

0.90
Ref.

Asthma/COPD
[0.88, 1.11]

0.94

[0.84, 1.06]

Ref.

Depression/Anxiety

Diabetes

96

[0.75, 0.96]

*

0.77
Ref.

[0.67, 0.87]

***

Table 3.3 Unadjusted Differences and Adjusted Odds Ratios for Bone Density Testing by Selected Characteristics of Female
Medicare Beneficiaries above 65 years of Age after Inverse Probability Treatment Weights. Surveillance Epidemiology and End
Results Program (SEER) - Medicare 2003-2011.
Yes

4,335

19.0

81.0

0.87

No

10,650

19.5

80.5

Ref.

Index Year

[0.79, 0.97]

**

0.81

[0.73, 0.90]

***

Ref.

***
2007

1,543

28.6

71.4

4.84

[4.15, 5.63]

***

4.79

[4.10, 5.59]

***

2008

1,602

31.2

68.8

5.45

[4.69, 6.33]

***

5.44

[4.68, 6.33]

***

2009

1,651

27.3

72.7

4.52

[3.88, 5.26]

***

4.49

[3.85, 5.23]

***

2010

1,726

28.3

71.7

4.63

[3.99, 5.37]

***

4.50

[3.87, 5.23]

***

2011
2003, 2004, 2005,
2006

1,944

28.0

72.0

4.47

[3.86, 5.17]

***

4.38

[3.78, 5.08]

***

6,519

7.5

92.5

Ref.

County% Hispanics

Ref.

***

6.81

3,772

19.9

80.1

1.29

[1.10, 1.51]

**

1.27

[1.08, 1.49]

**

17.00

3,656

19.9

80.1

1.42

[1.17, 1.71]

***

1.43

[1.18, 1.74]

***

42.99

3,791

22.9

77.1

2.05

[1.62, 2.59]

***

2.09

[1.65, 2.65]

***

2.23

3,766

14.7

85.3

Ref.

12.43

3,829

19.5

80.5

0.96

[0.83, 1.10]

16.71

3,691

19.0

81.0

0.85

[0.73, 0.99]

25.20

3,721

19.3

80.7

0.78

[0.65, 0.94]

Ref.

County% Less Than High School
0.94

[0.82, 1.08]

*

0.84

[0.72, 0.98]

*

**

0.75

[0.62, 0.90]

**

8.46
3,744
19.7
80.3
Ref.
Ref.
Note. Based on 3,029 female Medicare beneficiaries with Diffuse Large B-Cell Lymphoma and a random sample of 11,956
female beneficiaries without any cancer who resided in SEER areas. Weighted percentages were derived with using inverse
probability treatment weights. COPD: Chronic Obstructive Pulmonary Disease; PCP: Primary care physician; Sig.
significance level.
***p<.001 **.001< p<.01 *.01< p<.05
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Appendix 3.1 Flowchart of Sample Selection for Female Medicare Beneficiaries with Diffuse Large B-Cell
Lymphoma.
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Appendix 3.2 Flowchart of Sample Selection for Female Medicare Beneficiaries with No Cancer.
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Chapter 4: Impact of Diffuse Large B-Cell Lymphoma on the Costs of Chronic Conditions
in Elderly Medicare Beneficiaries

4.1 Abstract
Background. Newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) can increase
the cost burden of chronic conditions in elderly individuals. However, there is a lack of research
on change in costs of chronic conditions during DLBCL diagnosis, treatment, and follow-up as
compared to those without cancer. Objective. We examined the cost of common chronic
conditions and total cost among 5,455 DLBCL patients >65 years of age as compared to 14,770
individuals without cancer during a 3-year period of DLBCL diagnosis, treatment, and followup. Methods. We used a retrospective longitudinal study design with Surveillance,
Epidemiology, and End Results (SEER)-Medicare 2002-2013 data to estimate the costs of care
during 6 months’ intervals (pre-diagnosis: t1, t2 and post-diagnosis: t3, t4, t5, t6). All costs were
adjusted to 2013 constant dollars. Results. The difference in total cost between DLBCL and noncancer patients increased substantially from t1 ($468.8) to t3 (treatment period: $60,746.1) and t6
($6,614.8). DLBCL patients had a higher cost of heart conditions; however, they had
significantly lower costs of hypertension, asthma/chronic obstructive pulmonary disease, any
mental illness, and diabetes than non-cancer patients (all p< .001). Conclusions. DLBCL patients
incurred high total cost of care during the treatment period. The cardiotoxicity of DLBCL
treatment may have increased the cost of heart conditions. DLBCL patients might be receiving
less healthcare services for other conditions leading to lower short term costs of other common
chronic conditions. Future studies are recommended to investigate the cost-effectiveness of
increasing the quality of care for chronic conditions among DLBCL patients.
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4.2 Introduction
Advances in early detection and treatment of cancer among elderly individuals have led
to a substantial cost burden to Medicare, which is projected to further increase in the next
decade.1,2 The cancer specific and total costs of care vary widely according to the tumor site and
phase of care.1 Brain, pancreatic, gastric, esophageal, ovarian, and liver cancers account for
highest costs (> $40,000), as compared to breast, prostate, urinary bladder, and skin cancers.1
Non-Hodgkin’s Lymphoma is the most common blood cancer in the United States and is
commonly diagnosed in an aggressive form.3 The total annual cost of care for patients with
lymphoma has been found to be highest during the first 12 months after diagnosis (men:
$27,686, women: $28,882) and last year of life ($45,760, $51,763) as compared to annual cost in
between these phases ($3,993, $4,536).1 To date, no studies have compared the costs of care for
patients with lymphoma to non-cancer controls.
Medicare spending is further compounded for beneficiaries who have chronic conditions
in addition to cancer,4 which is ten times more common among elderly as compared to younger
individuals.5-7 For example, elderly renal cell cancer patients had higher one year Medicare costs
due to hyperlipidemia ($2745) and anemia ($2167) in 2005 as compared to cancer patients
without hyperlipidemia and anemia.8 Further, the additional 6-month cost of chronic conditions
among cancer survivors included $3418-$4385 for heart conditions; $5040-$8155 for respiratory
conditions; $7483-$7714 for diabetes; and $8004-$11,009 for mental conditions in Medicaid
enrollees in three states (Georgia, Maine, or Illinois) in 2003. Existing studies have examined the
additional cost burden of chronic conditions in patients with cancers such as colon9, renal cell8,
oral10, ovarian11, and thyroid12 cancers as compared to those without any chronic condition.
However, there is a dearth of evidence for the impact of cancer on the costs of chronic conditions
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before cancer diagnosis, during cancer treatment, and at follow-up periods, as compared to those
without cancer. Aggressive cancers such as Diffuse Large B-Cell Lymphoma (DLBCL) can have
varying effects on the costs of different chronic conditions, particularly in light of treatment
toxicities, which has not been previously explored.
DLBCL is the most common subtype of Non-Hodgkin’s lymphoma13 and requires
intensive treatment regimens such as chemo-immunotherapy and stem cell transplant.14,15
Chemotherapy with Doxorubicin is associated with cardiotoxicity16 while stem cell transplant
increases the risk of osteoporosis and fractures17,18 in DLBCL patients. These treatments can
specifically increase the cost of heart conditions, arthritis, and osteoporosis in DLBCL patients.
However, previous studies have found that patients with colorectal cancer were less likely to
receive care for heart conditions, diabetes, and COPD,19,20 which can decrease the short term cost
but increase the long term cost of these chronic conditions. Hence, the diagnosis and treatment of
DLBCL can selectively increase or decrease the cost of some chronic conditions, which has
implications for resource allocation and bundled payments for DLBCL.
The Centers for Medicare and Medicaid Services (CMS) launched a new bundled
payment model for cancer care called the ‘Oncology Care Model’ in 2016.21 This model will be
implemented over next five years and will reward participating physician group practices for
reducing the costs of care while meeting the benchmark quality measures. It is important to
examine the total costs and the costs of common chronic conditions among DLBCL patients to
inform the target costs for performance-based payments under this model. The study findings
will also highlight the potential benefits of early prevention, detection, and chronic disease
management efforts for DLBCL patients.
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4.3 Theoretical Framework
To date, most existing studies dealing with costs of care have examined the individual
characteristics including gender, race, age, education, and income, while less attention has been
paid to the societal or contextual factors.22-2627 Societal and environmental factors such as
county level racial/ethnic composition, availability of healthcare facilities, and transportation
have a significant impact on healthcare utilization, thereby affecting the costs of care.28-31 For
example, blacks had higher healthcare utilization when they lived in a county with a higher
percentage of blacks.29 Higher availability of primary care physicians and non-rural area of
residence were associated with higher use of preventive services.32 Per-capita spending by
Medicare varies significantly across the different states as well.33
Since the costs of care are a result of decisions made at individual, societal, and
organizational levels,34 we used a multilevel Socio Ecological Model (SEM) as the theoretical
framework to analyze the cost of chronic conditions and total cost among DLBCL patients.35,36
Previous studies have used the SEM to examine the healthcare utilization of patients with or
without cancer.37-41 According to the SEM, the utilization of healthcare services is determined by
following individual and contextual factors35,36,42 : 1) Intra-personal factors: include unique
socio-demographic characteristics of individuals such as age, sex, race, stage of DLBCL, and
DLBCL treatments; 2) Inter-personal factors: consist of racial/ethnic composition of county
measured by percentage of Blacks and Hispanics in the county; 3) Healthcare system factors:
include the availability of hospitals and physicians in the county which facilitate the use of
healthcare services; and 4) Community factors: consist of the surrounding geographical area
including SEER region, urban/rural region, and county level poverty, education, and average
travel time.36,37,43 Therefore, the purpose of this study is to examine the costs of care for common
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chronic conditions and total costs among elderly Medicare beneficiaries with DLBCL over a 3year study period as compared to beneficiaries without any cancer.
4.4 Methods
4.4.1 Study Design
This study used a retrospective longitudinal study design with 12 month pre-index and 24
month post-index phases. For DLBCL patients, we defined the pre-index and post-index phases
using the DLBCL diagnosis as the index date. For non-cancer patients, we used a random
inpatient or outpatient Medicare claim service date to identify the pre-index and post-index
phases. We divided the pre-index and post-index phases into six months’ intervals (t1-t6). For
DLBCL patients, the pre-index phase consisted of baseline (t1) and pre-diagnosis (t2) and postindex phase comprised of treatment (t3), post-treatment (t4), short follow-up (t5), and long
follow-up (t6) periods.
4.4.2 Data Sources
We utilized the following data sources for this study: 1) Surveillance, Epidemiology and
End Results Program (SEER) data: SEER is an epidemiologic cancer surveillance system which
collects information on patients with incident cancers residing in 20 cancer registry areas (Alaska
Native Tumor Registry, Arizona Indians, Cherokee Nation-Oklahoma, Connecticut, Detroit,
Atlanta-Georgia, Greater California, Greater Georgia, Hawaii, Iowa, Kentucky, Los Angeles,
Louisiana, New Jersey, New Mexico, Rural Georgia, San Francisco-Oakland, San JoseMonterey, Seattle-Puget Sound, and Utah).44 SEER contains data on cancer patient’s
demographic characteristics, site and date of cancer diagnosis, stage and grade of cancer (e.g.,
Ann Arbor DLBCL stage, and region and rurality of resident area. 2) Random sample of 5%
Medicare beneficiaries: We used this data to derive a comparison group of Medicare
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beneficiaries without any cancer (except basal cell carcinoma) who resided in SEER areas. 3)
Medicare claims data: We linked the Medicare claims data with SEER registry data to obtain
detailed information on use of healthcare services and their costs. 4) Area Health Resource File
(AHRF): We used the publicly available AHRF data45 to obtain information on the county level
inter-personal, healthcare system, and community factors.
4.4.3 Study Sample
We included 5,455 DLBCL patients who were aged >66 years with a primary diagnosis
of DLBCL (International Classification of Diseases for Oncology - Third Revision (ICD-O3)/World Health Organization 2008 codes: 13, 14, 15, 16) during 2003-2011. We included
patients who had only one primary cancer (except basal cell carcinoma) and whose cancer was
not diagnosed from autopsy. For the comparison group, we selected a 10% random sample of
Medicare beneficiaries with >66 years of age from the non-cancer patient dataset who resided in
SEER areas and did not have any cancer (except basal cell carcinoma).
We applied the following exclusion criteria to both DLBCL and non-cancer patients: 1)
those with End Stage Renal Disease (ESRD); 2) not alive during the study period; 3) enrolled in
managed care plans during study period; 4) not continuously enrolled in Medicare parts A and B;
5) not having any Primary Care Physician (PCP) visit during the study period; and 6) having
missing values for age, sex, race, region, or ESRD.
4.4.4 Measures
Dependent variables. We analyzed the following direct medical costs of care as
dependent variables: 1) disease specific and overall cost of the following chronic conditions –
arthritis, asthma/COPD, any heart condition, any mental illness, diabetes, hypertension,
hyperlipidemia, and osteoporosis. We used the payments made by Medicare for inpatient (Part
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A), outpatient and physician services (Part B), and home health agency (HHA) services for these
chronic conditions to estimate these costs; 2) total cost of care including all payments made by
Medicare for part A, part B, HHA, and Durable Medical Equipment (DME) claims for any health
condition.46 Similar to previous studies,1,47 we used payments made by Medicare, instead of
billed charges, to measure the true cost of care. All costs were adjusted to 2013 dollars by using
the consumer price index for medical care.48
Cancer Status. The key independent variable for this study was the diagnosis of DLBCL
as compared to having no cancer. The DLBCL diagnosis belonged to the domain of intrapersonal factors from the SEM.
SEM Independent Variables
Our study included both time varying and time invariant factors. The independent
variables of tobacco use and chronic conditions (arthritis, diabetes, any heart condition,
depression/anxiety, and asthma/COPD) were time varying and were measured during each time
interval from t1 to t6. The intra-personal factors of cancer treatments (chemo-immunotherapy,
radiotherapy, and stem cell transplant) for DLBCL patients were measured during the post-index
phase of two years. All other intra-personal, inter-personal, healthcare system, and community
factors were measured during the one year pre-index phase.
Intra-personal factors consisted of: 1) age at index date; 2) sex; 3) race; 4) arthritis
(osteoarthritis or rheumatoid arthritis); 5) diabetes; 6) any heart condition (cardiac arrhythmia,
coronary artery disease, or congestive heart failure); 7) depression or anxiety; and 8) respiratory
condition (Asthma or COPD). The following factors were measured for DLBCL patients only: 1)
Ann Arbor DLBCL stage (stage I, II, III or IV); 2) chemo-immunotherapy with Rituximab,
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Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone (R-CHOP); 3) radiotherapy; and
4) stem cell transplantation.
Inter-personal factors included 1) racial/ethnic isolation measured by percentage of
Blacks and Hispanics in the county; and 2) social/cultural cohesion estimated by the percentage
of non-English speaking individuals above 18 years of age in the county.
Healthcare system factors consisted of county level: 1) primary care physician shortage
area (Whole County, part of county, or no shortage); 2) number of hospitals per 10,000
individuals above 65 years of age; and 3) number of Federal Qualified Health Centers (FQHC)
per 10,000 individuals above 65 years of age.
Community factors included county level: 1) geographic region (Northeast, South,
North-Central, or West); 2) rurality: We used urban/rural recode to classify region into metro
(counties in metro areas with 250,000 to 1,000,000 population), urban (counties with urban
population of 2,500 to 20,000 population), and rural (counties with completely rural or <2,500
urban population)44; 3) percentage of individuals between 18 and 64 years of age without health
insurance; 4) percentage of individuals with below high school education; and 5) average travel
time to work. In addition to the SEM variables, we included time and index year as independent
variables.
4.4.5 Statistical Analyses
We conducted unadjusted analyses of non-normal cost data by using non-parametric
tests.49 Kruskal-Wallis rank tests analyzed the unadjusted differences in total cost and cost of all
chronic conditions among DLBCL and non-cancer patients.50 Further, we utilized repeated
measures Friedman test to analyze the unadjusted differences in cost between DLBCL and noncancer patients during t1-t6.51 For adjusted analyses, the population-averaged Generalized

107

Estimating Equations (GEE) with gamma distribution and log link analyzed the skewed cost
data.52 We used an unstructured correlation structure with GEE to account for the repeated
measures of costs among patients during t1-t6.52 Also, to reduce the observed selection bias
between DLBCL and non-cancer patients, we utilized Inverse Probability Treatment Weights
(IPTW) in all the adjusted analyses with GEE. We also analyzed the interaction between
patients’ race/ethnicity and racial/ethnic composition of county to elucidate its impact on the cost
of chronic conditions in this study. All analyses were conducted using SAS version 9.4.53
4.5 Results
4.5.1 Costs of Care by Characteristics of DLBCL Patients
The description of cost of chronic conditions and total overall cost during 12 months after
cancer diagnosis in DLBCL patients is presented in Table 4.1. The DLBCL patients had
substantial total annual cost ($80,220.9) after diagnosis. Those having depression/anxiety
($97,098.7), asthma/COPD ($92,341.2), any heart condition ($88,840.2), diabetes ($88,311.7),
and arthritis ($87,501.7) had higher average total cost as compared to those with no
depression/anxiety ($75,766.9), no asthma/COPD ($74,910.2), no heart condition ($64,326.2),
no diabetes ($75,748.4), and no arthritis ($76,782.0). The total annual cost of common chronic
conditions was $3,099.7 after cancer diagnosis. Tobacco users had a significantly higher cost of
chronic conditions ($4,424.5) than non-tobacco users ($3,017.7). Further, beneficiaries between
75-79 years of age as compared to 66-69 years, those living in North-East as compared to South,
those living in metro as compared to rural area, and those with a chronic condition as compared
to those without chronic condition had higher cost of chronic conditions and total costs of care.
4.5.2 Total Costs for DLBCL Patients
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Mean net costs of care (i.e., the difference in total cost between DLBCL and individuals
without cancer) are presented in Table 4.2. DLBCL patients had significantly higher costs than
non-cancer patients from t1 to t6. The 6-month cost difference between DLBCL and non-cancer
patients increased sharply from baseline, t1 ($468.8) to treatment period, t3 ($60,746.1) and
remained higher during long follow-up period, t6 ($6,614.8).
4.5.3 Costs of Chronic Conditions for DLBCL Patients
The change in cost of heart conditions and cost of all chronic conditions among
beneficiaries with DLBCL and those without cancer are presented in Figure 4.1. The change in
cost of heart conditions had the most impact on the cost of all chronic conditions, as both
significantly increased during the treatment period and decreased after the treatment was over.
The cost of all chronic conditions of DLBCL patients remained greater than baseline during the
follow-up periods. For beneficiaries without cancer, the cost of chronic conditions showed a
random increase during t2 and then constantly increased from t3 to t6. One explanation is the
increasing age of Medicare beneficiaries, and hence, an increase in the diagnosis and treatment
of chronic conditions.
The cost of chronic conditions was moderately higher among DLBCL patients as
compared to those without cancer (Table 4.2). The largest difference in total cost of all chronic
conditions was during t3 ($768.3). The cost of heart conditions accounted for the majority of cost
of chronic care among DLBCL patients (about 60%) (Table 4.3). The net cost of heart conditions
among DLBCL patients increased from t1 ($148.3) to t3 ($663.9) and then decreased during t6
($231.3). The cost of arthritis was lower among DLBCL patients as compared to patients without
cancer from t2 to t6. Also, the cost of hypertension and diabetes was lower among DLBCL
patients as compared to non-cancer patients during t1, t2, and t6 (Table 4.3).
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4.5.4 Impact of DLBCL on Cost of Chronic Conditions
From adjusted analysis, DLBCL patients had $586.8 higher adjusted cost of all chronic
conditions than patients without cancer (Table 4.4). The cost of chronic conditions was
significantly higher during t2, t3, t4, t5 and t6 as compared to t1. Among DLBCL patients, those
receiving radiotherapy had lower cost of chronic conditions.
With regard to the intra-personal factors, beneficiaries with age 70-74, 75-79, or >80
years as compared to 66-69 years, Blacks as compared to Whites, and tobacco users as compared
to non-tobacco users had significantly higher cost of chronic conditions. Further, females as
compared to males and those living in West or South as compared to North-East had
significantly lower costs of chronic conditions.
For county level factors, those living in counties with shortage of PCPs as compared to
counties with no shortage, counties with higher average travel time to work as compared to
counties with lower travel time, and counties with lower education level as compared to counties
with higher education level had higher cost of chronic conditions. There was a significant
interaction between patient’s race and the racial composition of the county. Black Medicare
beneficiaries living in a county with higher prevalence of Blacks had higher costs of chronic
conditions.
4.6 Discussion
In this study, we used SEER-Medicare data to examine the costs of common chronic
conditions and total cost of care among elderly Medicare beneficiaries with DLBCL as compared
to those without cancer. The net total costs of care increased substantially during the treatment
period among DLBCL patients, which was comparable to brain and pancreatic cancers.1 High
cost of care for DLBCL patients may be attributed to stem cell transplantation which was
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received by 64% of DLBCL patients and costs about $99,899 (autologous) to $203,026
(allogeneic) for 100 days of treatment.54,50 With an aging US population and increased life
expectancy, the cost burden of DLBCL to the Medicare program may increase further in the
future.
Outpatient costs constituted the largest component of the total cost of care for DLBCL.
This result is contrary to other cancers such as colorectal, cervical, and renal cancers for which
hospitalizations account for the largest share of cost estimates.1 The reason for high proportion of
outpatient costs is that chemo-immunotherapy or radiotherapy are the main treatments for
DLBCL which are provided in hospital outpatient or office/clinic settings.55-57 Further
exploration of the other components of costs such as prescription drugs for DLBCL patients is
warranted.
The impact of DLBCL on the costs of chronic conditions varied by the specific chronic
disease reflecting differences in the impact of DLBCL and its treatment on prognosis and care of
different chronic conditions. DLBCL patients had significantly higher cost of heart conditions
than non-cancer patients. The cost of heart conditions doubled during the treatment period and
accounted for the majority of cost of chronic conditions. One explanation is the use of
Doxorubicin based chemotherapy which causes cardiotoxicity such as development of
congestive heart failure and cardiomyopathy in lymphoma patients.58,59 Treatment related
cardiotoxicity can cause significant morbidity and mortality in lymphoma patients,60,61 which can
lead to higher long term costs. The bundled payment for cancer care under the CMS’s Oncology
Care Model should include the cost of heart conditions in DLBCL patients. Appropriate
management of heart conditions in DLBCL patients is critical and can reduce the long term costs
of care. Some primary prevention measures for high-risk patients include the use of dexrazoxane
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and the administration of doxorubicin in liposomal form or as continuous infusion.62 Also,
biomarkers and imaging studies can be used for early detection and treatment of heart conditions
in DLBCL patients.62
We found that among DLBCL patients, the cost of arthritis decreased over time from
DLBCL diagnosis to treatment and follow-up periods. Further, DLBCL patients had lower costs
of common conditions such as hypertension, asthma/COPD, mental illness, and diabetes during
the baseline and follow-up periods. There was no significant difference in the cost of arthritis,
hyperlipidemia, and osteoporosis in DLBCL patients as compared to non-cancer patients. These
results may reflect the lower receipt of care for these chronic conditions as found in previous
studies.19,20 This is concerning because DLBCL treatment increases the risk of osteoporosis,
fractures, and mental illness.18,63 Further research is required to investigate the impact of DLBCL
on the quality of care of these chronic conditions and their association with overall survival. The
inclusion of quality measures for chronic conditions in cancer care models might improve
chronic care and reduce long term costs of DLBCL patients.
Our findings suggest that costs of chronic care among cancer patients are influenced by
both individual and community level factors. We identified county level factors such as racial
composition, shortage of primary care, education level, and travel time were associated with cost
of chronic care. Blacks living in community with higher prevalence of blacks had higher cost of
chronic conditions. The efforts to reduce the costs of chronic conditions for cancer patients
should move beyond individual level factors and focus on the community level factors as well.
Our study has some limitations. We included Medicare beneficiaries with index date in
2003-2011. The Medicare Part D data, which provides prescription drug coverage, was available
from 2007. Hence, the majority of our study population was not enrolled in Part D, and we could
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not include the cost of medications in our cost estimates. Future studies with cost of prescription
drugs may further elucidate the impact of cancer on cost of chronic conditions. We also did not
include the out-of-pocket cost or co-payments by Medicare enrollees, which have been estimated
to be approximately 7% for Medicare Part A and 20% for Part B.1 Our study results may be
applicable to fee-for-service Medicare enrollees only.
The strengths of this study include the use of a large population-based data for patients
with newly diagnosed cancer. Since Medicare is the primary insurance payer for individuals
above 65 years of age, SEER-Medicare dataset provides the most complete information on the
use and cost of health services by beneficiaries with cancer. The direct medical cost estimates of
specific chronic conditions and DLBCL from our study can be used for resource allocation and
health policy design. The phase specific costs of care over 3 years for DLBCL patients can also
be used in cost-effectiveness analyses of interventions for disease prevention.
4.7 Conclusions
DLBCL patients had substantially higher total costs of care than Medicare beneficiaries
without cancer, which was primarily due to the treatments of chemo-immunotherapy and stem
cell transplant. However, the cost of all chronic conditions was only moderately higher among
DLBCL patients, and it varied depending on the specific chronic condition. The cost of heart
conditions was higher while the cost of other chronic conditions was either lower or similar to
non-cancer patients. Cardiotoxicity of DLBCL treatment may have increased the cost of heart
conditions among DLBCL patients. It is important to adjust the bundled payments of DLBCL
care for the cost of heart conditions. Even though risks for other conditions were increased in
DLBCL patients, the cost was lower, indicating they might be receiving suboptimal care for
other common chronic conditions. The quality of care for chronic conditions might need to be
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improved for DLBCL patients. Future studies are suggested to investigate the impact of other
common cancers such as breast, colorectal, and prostate cancer on the costs and quality of care
for chronic conditions. Further, the long-term cost effectiveness of increasing chronic disease
management among cancer patients needs to be examined.
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Figure 4.1 Change in Cost of Heart Conditions and Cost of All Chronic Conditions among Medicare Beneficiaries
with Diffuse Large B-Cell Lymphoma (DLBCL) and Beneficiaries without Cancer (2002-2013).

Cost of all chronic conditions included inpatient, outpatient, and home health costs for arthritis, asthma/chronic
obstructive pulmonary disease, any heart condition, any mental illness, diabetes, hypertension, hyperlipidemia, and
osteoporosis. The study period of 3 years was categorized in 6 months’ intervals (t1-t6). The pre-index phase (t1, t2)
was 12 months before DLBCL diagnosis and post-index phase (t3, t4, t5, t6) was 24 months after diagnosis.
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Table 4.1 Description of Mean Total Cost and Cost of Chronic Conditions among
Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma (DLBCL) during 12
Months after Cancer Diagnosis (2002-2013).
n
Total Cost, $ Sig. Chronic Cost, $ Sig.
Total
5,455
80,220.9
3,099.7
Sex
*
+
2,839.3
Female
3,029
79,598.4
Male
2,426
80,998.2
3,424.9
Age (years)
***
***
66-69
1,071
81,471.2
2,640.7
70-74
1,374
83,406.9
2,392.9
75-79
1,373
84,834.4
3,772.4
>80
1,637
72,859.5
3,429.1
Race
+
White
4,796
80,041.0
3,056.8
African American
190
80,109.6
4,677.5
Hispanic
120
88,400.9
3,477.5
Others
349
79,942.3
2,699.5
Marital status
***
Married
3,123
81,655.5
3,000.8
Separated/Divorced/
Widowed
1,660
78,622.8
3,361.7
Unmarried
372
85,446.4
3,483.6
Region
***
***
North Central
720
77,346.3
3,306.8
Northeast
1,113
87,656.8
4,134.9
South
1,267
75,401.1
2,825.0
West
2,355
80,178.7
2,694.9
Rurality
***
***
Rural
115
68,590.1
2,658.9
Urban
815
74,707.2
2,657.0
Metro
4,525
81,509.6
3,190.6
Dual eligibility
+
***
Yes
294
86,246.1
5,056.7
No
5,161
79,877.7
2,988.2
Any heart condition
***
***
Yes
3,537
88,840.2
4,395.3
No
1,918
64,326.2
710.4
Asthma/COPD
***
***
Yes
1,662
92,341.2
4,421.3
No
3,793
74,910.2
2,520.6
Depression/Anxiety
***
***
Yes
1,139
97,098.7
4,458.4
No
4,316
75,766.9
2,741.1
Arthritis
***
***
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Yes
1,750
87,501.7
4,208.0
No
3,705
76,782.0
2,576.2
Diabetes
***
***
Yes
1,942
88,311.7
4,626.8
No
3,513
75,748.4
2,255.5
Tobacco use
***
Yes
318
84,874.1
4,424.5
No
5,137
79,932.9
3,017.7
DLBCL stage
***
Stage I
1,813
72,724.4
2,964.0
Stage II
1,066
82,795.0
3,249.3
Stage III
812
83,118.8
3,033.1
Stage IV
1,391
89,974.9
3,123.6
Chemo-immuno therapy
***
**
Yes
5,007
84,677.5
3,099.1
No
448
30,412.9
3,106.2
Radiotherapy
***
Yes
1,629
77,184.5
2,810.7
No
3,826
81,513.8
3,222.8
Stem cell transplant
***
Yes
3,479
82,594.2
3,090.2
No
1,976
76,042.6
3,116.4
Primary care shortage
area
Part county
2,748
81,028.2
3,130.3
Whole county
1,848
80,122.6
2,949.1
No shortage
859
77,850.3
3,325.6
Note. Based on 5,455 Medicare beneficiaries with Diffuse Large B-Cell Lymphoma (DLBCL) > 66 years of age
who resided in Surveillance, Epidemiology, and End Results program (SEER) areas. Total cost included all
inpatient, outpatient, home health agency, and durable medical equipment costs. Cost of chronic conditions included
inpatient, outpatient, and home health agency costs for arthritis, asthma/COPD, any heart condition, any mental
illness, diabetes, hypertension, hyperlipidemia, and osteoporosis. All costs were adjusted to 2013 constant dollars.
Significance values (Sig.) were derived from Kruskal-Wallis tests.
COPD: Chronic Obstructive Pulmonary Disease.
***p<.001 **.001< p<.01 *.01< p<.05 +.05<p<.1
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Table 4.2 Differences in Total Cost and Cost of
Chronic Conditions between Medicare Beneficiaries
with Diffuse Large B-Cell Lymphoma (DLBCL) and
Beneficiaries without Cancer (2002-2013).
Total cost, $
Time
DLBCL
No Cancer
Net Cost
Sig.
t1
3,406.6
2,937.8
468.8
***
t2
5,123.4
3,701.5
1,421.9
t3
64,228.9
3,482.8
60,746.1
t4
15,992.1
3,236.1
12,756.0
t5
10,586.1
3,519.7
7,066.4
t6
10,543.6
3,928.8
6,614.8
Cost of chronic conditions, $
Sig.
DLBCL
No Cancer
Net Cost ***
t1
1,029.2
894.2
135.0
t2
1,084.7
1,187.3
-102.7
t3
1,765.7
997.4
768.3
t4
1,334.0
1,012.9
321.1
t5
1,232.8
1,018.8
214.1
t6
1,286.5
1,123.3
163.1
Note. Based on 5,455 Medicare beneficiaries with Diffuse Large B-Cell Lymphoma and 14,770 beneficiaries
without cancer who were >66 years of age and resided in Surveillance, Epidemiology, and End Results program
(SEER) areas. Total cost included all inpatient, outpatient, home health agency, and durable medical equipment
costs. Cost of chronic conditions included inpatient, outpatient, and home health agency costs for arthritis,
asthma/COPD, any heart condition, any mental illness, diabetes, hypertension, hyperlipidemia, and osteoporosis. All
costs were adjusted to 2013 constant dollars. The study period of 3 years was categorized in 6 months’ intervals
(pre-index: t1, t2 and post-index: t3, t4, t5, t6). Significance values (Sig.) were derived from Friedman's tests.
***p<.001
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Table 4.3 Description of Cost of Common Chronic
Conditions among Medicare Beneficiaries with Diffuse
Large B-Cell Lymphoma (DLBCL) and Beneficiaries
without Cancer (2002-2013).
Time
DLBCL
No Cancer Net Cost, $ Sig.
Heart conditions, $
***
t1
576.7
428.4
148.3
t2
635.1
698.8
-63.7
t3
1,164.8
500.9
663.9
t4
814.7
496.0
318.7
t5
743.5
504.7
238.8
t6
794.0
562.6
231.3
t1
t2
t3
t4
t5
t6
t1
t2
t3
t4
t5
t6
t1
t2
t3
t4
t5
t6
t1
t2
t3
t4
t5
t6
t1
t2
t3
t4

Diabetes, $
71.2
67.0
190.9
123.1
91.1
92.6
Arthritis, $
205.9
192.8
45.6
140.4
157.4
147.0
Hypertension, $
67.3
81.6
149.6
95.2
76.7
96.2
Asthma/COPD, $
28.77
43.23
116.27
56.16
57.43
62.10
Mental Illness, $
46.25
28.64
66.68
74.62

***
79.6
73.0
92.2
86.8
86.7
97.6

-8.3
-5.9
98.7
36.3
4.4
-5.0

177.7
196.8
158.0
181.0
161.0
176.4

28.3
-4.0
-112.3
-40.5
-3.6
-29.5
***

85.1
87.4
106.0
95.2
91.4
105.0

-17.8
-5.8
43.7
0.1
-14.7
-8.8
***

38.54
37.22
51.88
60.73
59.96
63.88

-9.77
6.01
64.39
-4.57
-2.53
-1.78

55.24
65.52
56.88
62.81

-8.99
-36.88
9.80
11.81

***
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t5
t6

71.94
82.52
-10.58
61.45
81.31
-19.86
Hyperlipidemia, $
t1
26.00
23.57
2.43
t2
27.35
22.25
5.10
t3
15.70
24.24
-8.54
t4
19.69
23.81
-4.12
t5
22.74
23.88
-1.14
t6
23.23
25.70
-2.47
Osteoporosis, $
t1
7.08
6.24
0.84
t2
9.00
6.43
2.57
t3
16.03
7.34
8.69
t4
10.13
6.65
3.48
t5
12.11
8.67
3.44
t6
9.98
10.85
-0.87
Note. Based on 5,455 Medicare beneficiaries with Diffuse Large B-Cell Lymphoma and 14,770 beneficiaries with
no cancer who were >66 years of age and resided in SEER areas. The cost of chronic conditions included inpatient,
outpatient, and home health agency costs. All costs were adjusted to 2013 constant dollars. The study period of 3
years was categorized in 6 months’ intervals (pre-index: t1, t2 and post-index: t3, t4, t5, t6). Significance values
(Sig.) were derived from Friedman's tests. COPD: Chronic Obstructive Pulmonary Disease
***p<.001.
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Table 4.4 Parameter Estimates from Generalized Estimating
Equations on Cost of Chronic Conditions among Medicare
Beneficiaries with Diffuse Large B-Cell Lymphoma (DLBCL) as
compared to Beneficiaries without Cancer (2002-2013).
Adjusted
β
SE
Sig.
cost, $
Intercept
6.190 0.130 ***
489.4
DLBCL
Yes
0.182 0.035 ***
586.8
No Cancer
Ref.
Time
Pre-Diagnosis
0.233 0.046 ***
617.7
Treatment
0.217 0.043 ***
608.0
Post-Treatment
0.178 0.046 ***
584.5
Short Follow-up
0.151 0.045 ***
569.1
Long Follow-up
0.233 0.044 ***
617.7
Baseline
Ref.
Age (Years)
70-74
0.253 0.048 ***
630.5
75-79
0.424 0.049 ***
747.7
>80
0.582 0.045 ***
875.9
66-69
Ref.
Sex
Female
-0.160 0.033 ***
418.6
Male
Ref.
Race
Black
0.275 0.062 ***
644.5
Hispanic
0.204 0.109
600.0
Others
0.014 0.064
496.3
White
Ref.
Region
North-Central
-0.070 0.064
456.7
West
-0.290 0.053 ***
367.3
South
-0.300 0.063 ***
364.1
Northeast
Ref.
Rurality
Urban
0.142 0.099
564.2
Metro
0.190 0.102
591.8
Rural
Ref.
Tobacco use
Yes
1.180 0.069 *** 1,590.7
No
Ref.
County% Blacks
4.43
0.017 0.053
497.8
9.88
0.167 0.061 **
578.1
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30.60
0.108 0.067
545.2
1.21
Ref.
County% FQHC
0.36
-0.130 0.057 *
429.7
0.94
-0.080 0.058
449.8
3.84
-0.100 0.055
444.0
0.01
Ref.
Primary care shortage area
Part county
0.071 0.052
525.6
Whole county
0.128 0.057 *
556.3
No shortage
Ref.
County average travel time
24.09
0.027 0.049
502.6
27.42
0.054 0.051
516.4
30.95
0.138 0.055 *
561.9
19.62
Ref.
County% Less Than High
School Education
12.23
0.086 0.050
533.3
16.24
0.287 0.050 ***
652.1
24.98
0.284 0.055 ***
649.9
8.41
Ref.
Note. Based on 5,455 Medicare beneficiaries with Diffuse Large B-Cell Lymphoma and 14,770 beneficiaries
without any cancer > 66 years of age who resided in SEER areas. FQHC: Federal Qualified Health Center; SE:
standard errors; Sig: significance level. The adjusted cost of chronic conditions was derived from Generalized
Estimating Equations with gamma distribution and log link. All costs were adjusted to 2013 constant dollars.
***p<.001 **.001< p<.01 *.01< p<.05
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Appendix 4.1 Description of One-Year Total Cost and Cost of Chronic
Conditions among Medicare Beneficiaries >66 Years of Age without Cancer
(2002-2013).
Total Chronic
n
Total Cost, $
sig
Cost, $
Total
14,770
6,718.8
2,010.3
Sex
***
Female
9,479
6,939.5
2,018.9
Male
5,291
6,323.5
1,994.8
Age (years)
***
66-69
4,452
5,078.1
1,523.0
70-74
3,914
6,110.7
1,985.1
75-79
2,786
7,396.4
2,140.1
>80
3,618
8,873.9
2,537.1
Race
+
White
11,885
6,577.0
1,908.1
African American
1,217
8,643.5
2,987.5
Hispanic
379
8,211.9
2,841.0
Others
1,289
5,769.9
1,785.5
Region
***
North Central
1,752
7,095.8
2,127.7
Northeast
2,885
7,091.6
2,358.9
South
3,779
6,189.2
1,919.6
West
6,354
6,760.6
1,873.5
Rurality
***
Rural
320
6,391.9
1,541.0
Urban
2,278
6,324.7
1,887.1
Metro
12,172
6,801.2
2,045.7
Any heart condition
***
Yes
5,749
12,027.2
4,067.9
No
9,021
3,335.8
699.0
Asthma/COPD
***
Yes
2,734
12,476.6
3,965.8
No
12,036
5,410.9
1,566.1
Depression/Anxiety
***
Yes
1,913
14,617.1
3,814.5
No
12,857
5,543.6
1,741.8
Arthritis
***
Yes
4,372
10,874.3
3,497.9
No
10,398
4,971.6
1,384.8
Diabetes
***
Yes
4,845
9,443.0
2,959.6
No
9,925
5,389.0
1,546.8
Tobacco use
***
Yes
464
13,312.3
4,812.4

sig
***

***

***

***

***

***

***

***

***

***

***
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No
14,306
6,505.0
1,919.4
Primary care shortage
area
Part county
7,094
6,514.0
1,997.9
Whole county
5,511
7,185.0
2,115.3
No shortage
2,165
6,203.2
1,783.5
Note. Based on 14,770 Medicare beneficiaries with no cancer > 66 years of age who resided in Surveillance,
Epidemiology, and End Results program (SEER) areas. Total cost included all inpatient, outpatient, home health
agency, and durable medical equipment costs. Cost of chronic conditions included inpatient, outpatient, and home
health agency costs for arthritis, asthma/COPD, any heart condition, any mental illness, diabetes, hypertension,
hyperlipidemia, and osteoporosis. All costs were adjusted to 2013 constant dollars. Significance values (Sig.) were
derived from Kruskal-Wallis tests.
COPD: Chronic Obstructive Pulmonary Disease.
***p<.001 **.001< p<.01 *.01< p<.05 +.05<p<.1
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Appendix 4.2 Parameter Estimates from Generalized Estimating
Equations on Cost of Chronic Conditions among Medicare
Beneficiaries with Diffuse Large B-Cell Lymphoma > 66 Years of
Age (2002-2013).
Adjusted
β
SE
Sig.
cost, $
Intercept
6.650 0.234 ***
772.3
Time
Pre-Diagnosis
0.094 0.085
848.5
Treatment
0.545 0.078 ***
1,331.8
Post-Treatment
0.340 0.085 ***
1,084.7
Short Follow-up
0.261 0.086 **
1,002.5
Long Follow-up
0.295 0.084 ***
1,037.6
Baseline
Ref.
Age (Years)
70-74
75-79
>80
66-69
Sex
Female
Male

0.193
0.377
0.391
Ref.

0.088
0.086
0.081

*
***
***

936.8
1,125.7
1,142.1

-0.280
Ref.

0.055

***

585.2

African American
Hispanic
Others
White

0.389
-0.060
0.072
Ref.

0.135
0.191
0.122

**

1,139.0
730.5
830.3

North-Central
West
South
Northeast

-0.090
-0.360
-0.270
Ref.

0.103
0.080
0.085

Urban
Metro
Rural

0.218
0.318
Ref.

0.191
0.185

0.579
Ref.

0.109

-0.100
-0.060
0.047
Ref.

0.076
0.082
0.073

0.884
Ref.

0.119

0.032

0.110

Race

Region
***
**

706.7
537.9
591.9

Rurality

Medicaid Dual Eligible
Yes
No
DLBCL stage
Stage II
Stage III
Stage IV
Stage I
Tobacco use
Yes
No
Chemo-immuno therapy
Yes

960.7
1,061.2

***

1,377.3

696.0
726.6
809.4

***

1,870.2

797.3
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No
Radiotherapy
Yes
No

Ref.
-0.120
Ref.

0.059

*

685.4

Stem cell transplant
Yes
-0.050 0.057
734.7
No
Ref.
Note. Based on 5,455 Medicare beneficiaries with Diffuse Large B-Cell Lymphoma > 66 years of age who resided
in SEER areas. FQHC: Federal Qualified Health Center; SE: standard errors; Sig: significance level. The adjusted
cost of chronic conditions was derived from Generalized Estimating Equations with gamma distribution and log
link. All costs were adjusted to 2013 constant dollars. ***p<.001 **.001< p<.01 *.01< p<.05
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Chapter 5: Discussion

5.1 Results Summary and Discussion
The current study investigated the impact of newly diagnosed DLBCL on primary care
and costs of care among elderly patients with DLBCL as compared to Medicare beneficiaries
without cancer. Owing to the dearth of research on the impact of DLBCL on primary care and
costs, we conducted this study to fill a critical knowledge gap and inform interventions for early
disease prevention and chronic disease management among elderly patients with DLBCL.
Specifically, our study examined the impact of newly diagnosed DLBCL on visits to PCPs and
other medical specialists and costs of common chronic conditions before DLBCL diagnosis,
during DLBCL treatment, and at follow-up periods as compared to Medicare beneficiaries
without cancer. The study also analyzed the receipt of mammography and bone mineral density
testing (BDT) by women with DLBCL during two years after DLBCL diagnosis as compared to
women without cancer. We used a comprehensive Social Ecological Model (SEM) to examine
individual as well as societal factors that may play a role in the care of DLBCL patients.1,2
One of the main goals of the study was to understand how having a DLBCL diagnosis
influences a patient’s utilization of primary care services in comparison to patients without
cancer. DLBCL patients had more visits to PCPs and some specialists as compared to those
without any cancer, even after adjusting for intra-personal, inter-personal, healthcare system, and
community factors. Surprisingly, even though DLBCL patients had more PCP visits, the rates of
mammography and BDT were similar between female DLBCL and non-cancer patients. After
controlling for PCP visits, female DLBCL patients were less likely to receive either
mammography or BDT as compared to women without cancer, which is concerning as female
DLBCL patients are at a greater risk of breast cancer and osteoporosis. The prioritization of
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acute cancer care might have resulted in suboptimal preventive screenings in DLBCL patients.
Another important reason for the less-than-ideal receipt of preventive services among DLBCL
patients is limited provider and patient time. The providers face the difficulty of integrating
many screenings recommended by the USPSTF along with the competing demands of intensive
DLBCL treatment.3 The patients are also engaged with the tremendous increase in number of
diagnostic and therapeutic approaches for DLBCL. Further, 80-100% of cancer patients report
cancer-related fatigue in addition to the treatment side effects.4 Amid the burden of DLBCL
treatment and its effects, patients may not adhere to guidelines for preventive services. The
providers and patients must choose which preventive services will deliver the largest
improvement in quality of life and overall survival. Some previous studies have ranked the
USPSTF recommended preventive services with regard to their health impact and costeffectiveness.5 Although all preventive services are important and should be provided, giving
such information on the relative importance of preventive services to providers and patients can
assist in deciding where to focus their prevention efforts.
There is also a need for individualized risk-based preventive care of patient based on the
treatment received, age of patient, and risk of developing a disease. We did not find a significant
relationship of the type of DLBCL treatment such as radiotherapy and stem cell transplant with
mammography and BDT. Increasing mammography screening of patients receiving
chemotherapy and more BDT of those receiving stem cell transplant can increase the early
detection of breast cancer and osteoporosis and hence, reduce the morbidity and mortality from
these conditions. Further, women between 70-74 years of age were less likely to have
mammography and women above 70 years of age were less likely to receive BDT than women
between 66-74 years of age. Continued mammography screening for women aged 70-74 years
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and BDT among women above 70 years of age is also needed, as recommended by the US
Preventive Services Task Force (USPSTF) guidelines. Currently, there is a lack of clinical
guidelines for preventive care of patients with different types of cancers and treatments. Future
development and refinement of such guidelines can further assist in prioritization of specific
preventive services depending on the risk of a particular cancer patient.
Our second goal was to examine the differences in visits to provider type and utilization
of care for different types of chronic diseases among DLBCL patients over the cancer care
trajectory. Although DLBCL diagnosis resulted in more visits to PCPs and some specialists and
increased the total cost of chronic conditions, the impact of DLBCL varied as a function of the
type of provider specialty and the type of chronic disease. For instance, visits to cardiologists,
pulmonologists, and endocrinologists and cost of cardiac conditions increased during the
treatment period. The significant increase in visits to endocrinologists and cost of cardiac
conditions may be due to chemotherapy with Doxorubicin among DLBCL patients, which can
cause significant cardiotoxicity including the development of congestive heart failure and
cardiomyopathy in lymphoma patients.6,7 Interventions to reduce the long terms costs of DLBCL
can be more effective by increasing the preventive care for heart conditions before and during
treatment, especially for patients with pre-existing cardiac illnesses. Some primary prevention
measures for cardiac illnesses include the use of biomarkers and imaging studies for early
detection and administration of dexrazoxane for preventive treatment.62 Further, for the
‘Oncology Care Model’ with bundled payments for cancer patients,8 policy makers and
researchers should consider the cost of heart conditions while setting benchmarks for the
reimbursements of care for DLBCL.
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Although the utilization of care for cardiac conditions increased, the visits to
rheumatologists and mental health specialists decreased during treatment and follow-up periods.
Further, the cost of arthritis decreased from DLBCL diagnosis to treatment and follow-up
periods. DLBCL patients also had lower costs of other conditions such as hypertension,
asthma/COPD, mental illness, and diabetes during the baseline and follow-up periods. There was
no significant difference in the cost of hyperlipidemia and osteoporosis as compared to noncancer patients. These findings may reflect lower quality of care for these chronic conditions as
found in some previous studies.9,10 One possible explanation is that patients might be engaged
with the sudden increase in treatments for DLBCL and may not have enough time or energy to
visit providers for chronic conditions. Currently there is a lack of studies examining this
phenomenon among patients with newly diagnosed cancer. Future studies might shed further
light on the reasons for poorer quality of care for chronic conditions among cancer patients.
Also, the diagnosis and treatment of DLBCL can lead to an increase in mental health conditions
such as anxiety, depression, post-traumatic stress disorder, and poorer health status.11-13 Even
though DLBCL patients in our study had an increased diagnosis of mental health conditions over
treatment and follow-up periods, their visits to mental health providers did not change. It is
critical to screen elderly DLBCL patients for mental health conditions during and after DLBCL
treatment and to refer suitable patients to mental health providers when necessary. Similarly,
DLBCL patients are at a greater risk of osteoporosis and fractures. Given the low rate of BDT
among elderly women, clinicians and other healthcare providers may consider using an
osteoporosis risk assessment tool14 to analyze the absolute fracture risk of women with DLBCL
and to provide BDT and appropriate osteoporosis treatments. Further research on the impact of
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DLBCL on quality of care of these chronic conditions and their association with overall survival
is warranted.
In addition to our two main study goals, we also explored the functionality of an
ecological model to help us understand the impact of DLBCL over the cancer care trajectory.
The use of an ecological model helped us identify additional environmental factors, which were
significantly related to the care of DLBCL patients. The racial composition of county was a
significant determinant of the visits to PCPs, as DLBCL patients living in counties with a higher
percentage of African Americans had less PCP visits. Further, the racial composition of county
had a significant interaction with the patient’s race on the total costs of chronic conditions.
African Americans living in counties with higher prevalence of African Americans had higher
total cost of chronic conditions. Those living in the South or West regions as compared to
Northeast had more PCP visits but less total cost of chronic conditions. Other significant societal
factors included the level of education and health insurance in the county. Medicare beneficiaries
with DLBCL living in counties with a lower education level had more PCP visits and higher total
cost of chronic conditions. Further, DLBCL patients living in counties with less health insurance
had fewer PCP visits. With respect to preventive care, DLBCL patients living in counties with
more travel time were less likely to have mammography and those living in counties with higher
prevalence of Hispanics were more likely to have BDT. These findings indicate the importance
of policy changes aimed at environmental and organizational factors in addition to individual
level factors for improving care and reducing costs among DLBCL patients. Given the lack of
environmental and organizational variables in many existing studies, it would be valuable for
more studies to analyze the contribution of environmental factors to the understanding of
primary care and costs among cancer patients.
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5.2 Study Limitations
Our study findings should be interpreted in the context of some limitations. First, the
study sample included elderly individuals enrolled in fee-for-service Medicare and without
Health Maintenance Organization (HMO) enrollment. Hence, the study findings may not be
applicable to younger patients, those enrolled in managed care or commercial insurance plans,
and those residing in non- Surveillance, Epidemiology, and End Results Program (SEER)
regions. In addition, for the second aim, our study was restricted to elderly women with DLBCL
between 65-74 years of age for mammography screening and above 65 years of age for BDT.
Therefore, the findings from aim 2 cannot be generalized to men and younger women. We used
the Health Care Financing Administration (HCFA) codes to determine the physician specialty in
this study which might underestimate the provider specialties in the Medicare claims. Further,
due to non-enrollment in Medicare Part D by most of our study sample, we could not include the
costs of prescription drugs in the costs of chronic conditions in our study.
5.3 Study Strengths
Despite some limitations, the current study contributed to the nascent literature on the
impact of DLBCL on visits to different provider specialties, preventive care, and the costs of
chronic conditions among elderly individuals with newly diagnosed DLBCL as compared to
Medicare beneficiaries without cancer. Our study examined the visits to other medical specialists
over a three-year time period spanning the cancer diagnosis, treatment, and follow-up periods,
which had not been examined in the literature previously. We used the SEER-Medicare database,
which is a nationally representative data to examine the care of elderly patients with newly
diagnosed cancer. Since Medicare is the primary insurance payer for individuals above 65 years
of age, SEER-Medicare dataset provides the most complete information on the use and cost of
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health services by beneficiaries with cancer. Also, a comprehensive SEM framework analyzed
the association of various personal and contextual factors with primary care and costs among
elderly DLBCL patients. Other strengths of this study include a robust study design with Inverse
Probability Treatment Weights (IPTW) adjusted analyses to reduce observed selection bias, a
non-cancer comparison group, and time varying diagnosis of chronic conditions. The direct
medical cost estimates of specific chronic conditions and DLBCL from our study can be used for
resource allocation and health policy design. The phase specific costs of care over 3 years for
DLBCL patients can also be used in cost-effectiveness analyses of interventions for disease
prevention.
5.4 Conclusions and Research Implications
Elderly Medicare beneficiaries with DLBCL were more likely to visit PCPs,
cardiologists, pulmonologists, and endocrinologists than non-cancer patients. Treatment adverse
effects and more frequent contact with the healthcare system may have led to an increased
diagnosis of other chronic conditions, which partially explained more visits to PCPs and some
specialists. Interventions to improve care-coordination among PCPs and specialists may need to
target the treatment period when coordination is most vulnerable. However, an increased
diagnosis of mental health conditions and other chronic conditions did not result in increased
visits to mental health specialists and other corresponding provider specialties. Elderly DLBCL
patients should be screened for mental health conditions and referred to mental health specialists
when necessary. Patients with pre-existing conditions and those receiving chemoimmunotherapy and stem cell transplant need extra attention for the care of chronic conditions.
Further research and interventions to improve the quality of care for these conditions among
patients with DLBCL are warranted.

Page | 142

Even though DLBCL patients had more PCP visits, female DLBCL patients were less
likely to receive mammography and BDT than women without cancer. Interventions to increase
the recommendations for mammography screening and BDT among women with DLBCL are
needed. Rates of mammography should especially be increased for elderly women receiving
chemo-immunotherapy and BDT for those receiving stem cell transplant. Risk assessment tools
for osteoporosis can further help in targeting the use of BDT and treatment of osteoporosis in
DLBCL patients. Further, due to the low rate of preventive care among Medicare beneficiaries,
future studies should investigate the impact of newly diagnosed cancer on the receipt of other
preventive services recommended by the USPSTF. With respect to the cost of care, DLBCL
patients had markedly higher total costs due to cancer treatment than Medicare beneficiaries
without cancer. The cost of all chronic conditions was only moderately higher among DLBCL
patients, and it varied for different types of chronic conditions. The cost of heart conditions was
higher while the cost of other common chronic conditions was lower among DLBCL patients
than those without cancer. Personalized medicine, through use of biomarkers and imaging
studies, for early detection and preventive drug therapies for treatment of cardiac illnesses may
reduce the cost of DLBCL patients. It is also critical to examine the long-term cost-effectiveness
of increasing chronic disease management in patients with cancer.
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